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Hyperglycemia in pregnancy is increasing in Tanzania; however, timely diagnosis is limited. 
This study therefore, aimed to establish the prevalence of hyperglycemia in pregnancy, risk 
factors and develop a simple method for identification of women with gestational diabetes 
mellitus in Tanzania. A cross-sectional study was conducted in Arusha City, between March 
and December, 2018 among 468 pregnant women at second and third trimesters. Blood 
glucose was tested using Gluco-Plus™ and the World Health Organization’s criteria, while 
insulin resistance was calculated using the Homeostasis Model of Assessment formula. 
Anthropometrics were assessed using standard procedure and knowledge on hyperglycemia 
in pregnancy, demographics, and maternal characteristics were collected through face-to-face 
interviews using a questionnaire. The prevalence of hyperglycemia in pregnancy was 16.2% 
(n = 76) of which 13% had gestational diabetes mellitus and 3.2% diabetes in pregnancy. 
Additionally, the prevalence of insulin resistance was 21% (n=49). Knowledge about 
hyperglycemia in pregnancy was low on existence (10.7%, n=50), effects (23%, n=14), 
symptoms (26%, n=13) and risk factors (30%, n=15). Hyperglycemia in pregnancy was 
significantly associated with body fat percentage ≥ 38, delivery macrosomic babies, insulin 
resistance, mid-upper arm circumference ≥ 28 cm and family history of type 2 diabetes 
mellitus. These risk factors, except insulin resistance, were used to develop a risk score which 
was simplified into risk factors checklist to identify women with gestational diabetes 
mellitus. The score correctly identified 98% of hyperglycemic women, with an area under the 
receiver operating characteristic curve of 0.971 (95% CI 0.955-0.993, p < 0.001), sensitivity 
of 0.980 and specificity of 0.458. The high prevalence of hyperglycemia in pregnancy creates 
a need for regular screening and management. Hence, the developed screening method can be 
validated for use when resources are limited to give priority to high risk women while 
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1.1  Background of the study   
Diabetes mellitus (DM) is a cluster of metabolic diseases characterized by hyperglycemia that 
results from defects in insulin secretion, insulin action, or both which is categorized as Type 
1 diabetes mellitus (T1DM), Type 2 diabetes mellitus (T2DM), or gestational diabetes 
mellitus (GDM) (American Diabetes Association [ADA], 2010). Although it is difficult to 
distinguish the types of diabetes mellitus at onset, the real diagnosis becomes more evident 
over time (ADA, 2017). Type 1 diabetes mellitus or juvenile-onset diabetes, which is termed 
as insulin dependent, results from a cellular-mediated autoimmune damage of the beta cells 
of the pancreas caused by autoimmune response (ADA, 2010). In this case the defense system 
of the body attacks the insulin-producing beta cells resulting in failure of the body to produce 
the insulin it needs (International Diabetes Federation [IDF], 2013; ADA, 2010). Type 2 
diabetes mellitus is the most common type of diabetes mellitus where the body produces 
insulin, but the production is either insufficient or uptake is ineffectual, leading to raised 
levels of glucose in the blood (IDF, 2013; ADA, 2010). At the molecular level, insulin 
resistance (IR) is usually a failure of insulin signaling, causing inadequate plasma membrane 
translocation of glucose transporter 4, which is the primary transporter for glucose into the 
cell to use as energy (Plows et al., 2018). The third type of diabetes mellitus, GDM, aligns 
with physiological alterations during pregnancy (World Health Organization [WHO], 2013).  
Hyperglycemia in pregnancy (HIP) is a common health problem resulting from either pre-
existing diabetes or development of IR, which is accompanied by impaired glucose tolerance 
with first recognition during pregnancy (Negrato & Gomes, 2013; WHO, 2013). In other 
words HIP is defined as any glucose intolerance that is first detected at any time during 
pregnancy (WHO, 2013; Hod et al., 2015). This study used HIP to include both GDM and 
DIP, because GDM is not the only form of hyperglycemia which may first be detected during 
pregnancy, as diabetes in pregnancy (DIP) is a more severe form of HIP in which diagnostic 
criteria and glucose levels are the same as those for non-pregnant adults (WHO, 2013; Hod et 
al., 2015). Therefore, it is important to combine both GDM and DIP to include pregnant 
women with pre-existing diabetes in planning interventions. Moreover, DIP increases 
complications because of the high level of hyperglycemia and the uncertainty as to whether 
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the onset of hyperglycemia was prior to pregnancy or during pregnancy (Hod et al., 2015). 
Furthermore, HIP should be considered because, in populations with high prevalence of 
T2DM but do not have access to screening before pregnancy, are at high risk for pre-existing 
diabetes mellitus (Kjos et al., 1990). 
During pregnancy, HIP in a form of GDM occurs due to pregnancy-induced changes in 
maternal glucose metabolism and insulin sensitivity, whereby demand for insulin production 
on the mother’s pancreas increases as pregnancy continues to grow. In most instances, 
women meet the increased insulin demand, but failure to accommodate results in poor 
glycemic control (Palani et al., 2014).   
Although HIP disappears after delivery if it is due to pregnancy, misdiagnosis and/or 
mismanagement may lead to short and long-term health risks to the mother and her new born 
within five to ten years post-delivery (IDF, 2017; Kitzmiller et al., 2007). Up to 36% of 
women with GDM, may experience abnormal glucose tolerance postpartum, creating a need 
for both short- and long-term follow-up to prevent poor pregnancy outcomes as well as 
T2DM, and GDM in subsequent pregnancies (Russell et al., 2006; Tovar et al., 2011; ADA, 
2013). Evidence shows that 2.6% to 38% of pregnant women with GDM developed T2DM 
within 12 weeks following delivery (Carson et al., 2013). Women with HIP experience; 
abortion/miscarriage (death before 20 weeks of gestation), and/or a pregnancy resulting into 
preterm birth (birth before 37 weeks of gestation), stillbirth (death after 20 weeks of 
gestation) and/or neonatal death (death within 28 days of life) (IDF, 2017; Wendland et al., 
2012).  
Furthermore, these women can deliver a macrosomic baby (> 4 kg at birth) and increase birth 
trauma (Hartling et al., 2013). Macrosomic infants are at risk of hypoglycemia soon after 
birth because their bodies continue producing extra insulin in response to the mothers’ excess 
glucose (Plows et al., 2018). Newborns with excessive body fat stores as a result of high 
maternal sugar levels during pregnancy, often continue to be overweight in childhood and 
adulthood which may increase the risk of developing non-communicable diseases (NCDs) 
such as diabetes (Palani et al., 2014).  It is also associated with caesarean section resulting 
from large for gestational babies (Wendland et al., 2012). Hyperglycemia in pregnancy can 
cause pregnant induced hypertension (PIH), a major risk factor for preeclampsia, which 
affects 25% of these women, in contrast to 5% of women without preexisting hypertension. 
3 
Also, the levels for hypertension may remain elevated beyond 12 weeks postpartum, leading 
into chronic hypertension (Carson et al., 2013).   
Globally, it is estimated that 21.3 million or 16.2% of live births involved women with some 
form of HIP (IDF, 2017). These estimations show that 86.4% of those cases were due to 
GDM, 6.2% due to diabetes detected prior to pregnancy and 7.4% due to other types of 
diabetes (including TIDM and T2DM) first detected in pregnancy (IDF, 2017). The majority 
(88%) of the HIP cases were in low- and middle-income countries, where access to maternal 
care is limited. The pooled prevalence of GDM in Africa was 13.6% and 14.28% in the sub-
Saharan African region (Muche et al., 2019). The reported high prevalence of HIP (GDM and 
DIP) globally, and in Africa, specifically, reveals a significant public health concern. The 
prevalence of different forms of HIP, especially GDM, often varies within a single nation 
depending on geo-local nuances in demographics, economics and ethnicities. For-example in 
Tanzania a higher prevalence was reported in urban areas with 18% in Dar es Salaam and 
about 20% in Kilimanjaro Region (Mwanri et al., 2014; Njete et al., 2018). 
The risk factors which predict the development of HIP in a form of GDM include: Family 
history of diabetes, GDM in previous pregnancy and obesity/overweight (Imoh et al., 2016). 
Overweight/obesity ≥ 25 kg/m2 have been reported to increase from 28% in 2015 to 31.5% in 
2018 among women of reproductive age (15-49 years of age) in Tanzania (Ministry of 
Health, Community Development, Gender, Elderly and Children [MoHCDGEC] et al., 2016; 
2018). Hence, specific consideration is required as the majority of women start pregnancy 
while overweight/obese, which increases their chance of developing NCDs including HIP. 
On the other hand a woman with tendency of delivery macrosomic babies and/or stillbirth in 
previous pregnancies, previous intrauterine fetal death (IUFD), and preterm delivery might 
have HIP in the previous pregnancies which was undiagnosed (Imoh et al., 2016).  
In addition, sedentary lifestyles, poor dietary intake, smoking habits, and extreme pregnancy 
weight gain accompanied by high body fat accumulation, places women at high risk for HIP. 
This is due to fact that, body fat percentage can alter body composition leading to HIP and 
other complications, such as pregnancy induced hypertension (PIH) and predisposition of the 
newborn to overweight or obese later in life (Jensen et al., 2005; Ay et al., 2009). It can also 
affect fetal growth; therefore, assessment of changes in body fat content is important to 
understand the effects of maternal health on neonate and future child health (Reilly et al., 
2005). The overt symptoms of GDM are rare, making it difficult to identify women who need 
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testing as it may be difficult to distinguish from normal pregnancy symptoms which need the 
inclusion of risk factors for easy identification of women who need additional tests. This 
creates a need for appropriate interventions to screen, prevent and/or manage HIP (IDF, 
2017).  
The Ministry of Health and Social Welfare (MoHSW) and Tanzania Diabetes Association 
through the Case Management Desk Guide, which is focusing on chronic NCDs such as 
cardiovascular disease, T2DM and cancer has included GDM. This guideline included GDM 
as a risk factor and criteria for screening DM although not well explored (MoHSW & 
Tanzania Diabetes Association, 2013). In addition, the Standard Treatment and Essential 
Medicines List guideline has included and reported that GDM screening has to be done using 
fasting plasma blood and 2 hours oral glucose tolerance test (OGTT) as well as management 
throughout pregnancy and post-delivery (MoHSW, 2013). Although GDM has been included 
in some guidelines in Tanzania, there is low emphasis on the antennal care (ANC) guidelines 
which may have contributed to low consideration of GDM in the regular ANC programs 
offered. This may be attributed by fragmentation of care caused by poor coordination of the 
health system and/ or emanating costs.   
The current Focused Antenatal Care (FANC), has abandoned the traditional ANC (Kearns et 
al., 2014), which involved numerous visits and accurate identification of high-risk 
individuals.  This traditional ANC was found to present challenges in resource-constrained 
settings which encouraged the exploration of the FANC model, based on an individualized, 
targeted approach, to detect complications as they arise (Kearns et al., 2014). This practice 
fails to recognize that, prevention is better than waiting until when the problem develops and 
subsequently treating.  
Furthermore, the FANC model suggests ANC visits to take place before 12 weeks, at 26 
weeks, at 32 weeks, and between 36-38 weeks with a strict checklist of assessments and 
interventions to be included in each of the four visits (Kearns et al., 2014). This is 
challenging because, women who do not attend all visits, do not receive important 
interventions, which may risk the health of both women and newborns. Hence, due to late 
initiation of ANC or poor attendance (Ramaiya et al., 2018), there is a need to include risk 
factor identification during the first visit or even before pregnancy for preventative purposes. 
These factors can help in self-identification before pregnancy and/or assessed during history 
taking and applied in the counselling session or during the regular ANC education programs. 
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Early diagnosis and identification of women at risk, is essential for proper management and 
treatment of GDM to prevent future complications (Mwanri et al., 2014).  
The FANC model integrates ANC with care and counselling related to several other 
conditions and women are immunized against tetanus, tested and treated for anaemia, vitamin 
A, or iodine deficiencies. They also receive testing and, if necessary, treatment for Human 
Immunodeficiency Virus or acquired immunodeficiency syndrome (HIV/AIDS), sexually 
transmitted infections (STIs), malaria and tuberculosis (Kearns et al., 2014) however, HIP 
screening and management has not been prioritized among services offered. The Tanzania 
National Health Policy on the other hand, has put more efforts  in  expanding,  improving  
and  distribution  of  the reproductive, maternal,  newborn, child  and  adolescent  health  
services  to  the  target  population. The main services are related to family planning, 
pregnancy, sexually transmitted diseases, gender based violence, violence   against   children, 
female genital mutilation, harmful traditional practices, breast and cervical cancer screening, 
prevention and treatment of infertility (MoHCDGEC, 2017). However, HIP (GDM and DIP) 
is not mentioned as a priority health condition in the health policy while this policy is the 
source of many health related guidelines.   
The implementation of maternal and child health programs in Tanzania may be affected by 
several drawbacks that have been reported in a study done to assess the capacity and 
capability of Tanzania health facilities to diagnose and manage GDM. These drawbacks 
include understaffing, late initiation of ANC and limited screening for GDM due to lack of 
equipment and supplies (Ramaiya et al., 2018). Also, the facility staffs were under-trained 
and received fewer refresher courses in diabetes. These ranges from 0–5% for diabetes as 
compared to hypertension (4–6%), other NCDs (0–16%), Prevention of Mother to Child 
Transmission (39%), management of postpartum bleeding (31%) and HIV/AIDs (31%) 
(Ramaiya et al., 2018). These drawbacks may have also affected the screening and 
management of diabetes including HIP which creates a need to address the existing gaps on 
screening, managements and knowledge, to better incorporate HIP in the ANC services. 
Evidence-based findings are thus urgently needed to provide best practice standards for 
testing, management and care of women with HIP (Hod et al., 2015).  
The guidelines for screening HIP in a form of GDM varies from universal to selective 
methods. The universal screening and diagnosis recommendation include oral glucose 
tolerance test (OGTT) using one step provision of 75 g or two steps provision of 50 g 
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followed by 100 g of glucose solution, and fasting glucose plasma test (Sharma et al., 2013; 
International Association of Diabetes and Pregnancy Study Group [IADPSG], 2010; WHO, 
2013; ADA, 2014). The common selective screening strategies include simple identifiable 
maternal and clinical risk factors (ADA, 2010). The fasting screening test needs a woman to 
stay without eating anything for 8-12 hours and OGTT needs a woman to remain in the ANC 
for more than 2 hours where multiple samples for analysis are needed increasing, the 
workload of the care providers and testing costs (Agarwal et al., 2011; Pastakia et al., 2017). 
The risk score can be a good option, but the identification of risk factors may be difficult and 
complex arithmetic’s are involved. Considering the doubling rate of the population and 
concomitant resource constraints, it is important to determine early predictors of pregnancy 
complications to plan for early prevention strategies (Lekva et al., 2010). Hence, as HIP 
contributes to poor pregnancy outcomes, it is important to be given priority like other 
pregnancy conditions listed in the FANC model. However, due to limited resources there is 
need to develop a screening method which is sensitive and administrable by lesser trained 
health workers or self-administered (Agarwal et al., 2011; Utza et al., 2017). This can give 
priority to high risk women for thorough glucose control before conception for effective 
preparations before pregnancy, throughout pregnancy, and during post-delivery period.  
Early identification of women at risk of HIP and performing additional testing in selected 
women, minimizes inconvenience for pregnant women, as well as saves time and healthcare 
costs (WHO, 2013). Hence, cost-effective models must be developed and individualized by 
country for optimal testing and managing of GDM given their specific burden of disease and 
resource gaps (Hod et al., 2015).  This study therefore, aimed to determine the prevalence of 
HIP, IR and their determinants to develop a simplified method which can be incorporated in 
ANC for identification of women with/at risk of GDM to prevent poor pregnancy outcomes 
where universal screening is challenging. The study also aimed to understand knowledge 
gaps on HIP, for appropriate intervention to enhance self-care among pregnant women.  
1.2  Statement of the problem    
Globally, child and maternal mortality is decreasing significantly, although Sub-Saharan 
Africa continues to have the highest child mortality at about twice the global mortality rate 
(Morton et al., 2017). In Tanzania, the rate of  under-5 mortality has decreased significantly 
from 81 in 2010 to 67 per 1000 death in 2015 while neonatal mortality has a slower decrease 
rate from 26 in 2010 to 25 deaths per 1000 in  2015. (National Burew of Statistics [NBS], 
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2011; MoHCDGEC et al., 2016).  Furthermore, maternal mortality ratio has increased from 
454 in 2010  to 556 deaths per 100 000 live births in 2015 (NBS, 2011; MoHCDGEC et al., 
2016). Most of these neonatal and maternal deaths could be prevented by providing high-
quality care during pregnancy and at birth, as children are most vulnerable in the first 28 days 
of life (neonatal period) (Morton et al., 2017). In addition, due to the doubling rate of 
overweight and obesity among Tanzanian women of reproductive age in urban areas 
(MoHCDGEC et al., 2016), many  women may start pregnancy while overweight or obese 
which increases their chances of developng NCDs such such as diabetes, and cardiovascular 
diseases.  
Therefore, inaction to maternal and child health agenda may lead to increasing mortality and 
morbidity burden in the future which can impact the social capital of the nation.  In this case, 
pregnancy as a window of opportunity for maternal and child health, has been given specific 
consideration in the Sustainable Development Goal number three (SDG 3), to reduce global 
maternal death to less than 70 per 100 000 live births, end preventable neonatal deaths to 
atleast 12 per 1000 live births, and children under five years to 25 per 1000 live births 
(Morton et al., 2017). It also aims to  reduce by one third premature mortality from NCDs 
through prevention and treatments (Morton et al., 2017). This created a need to conduct a  
study in Arusha District, which has a high prevalence of T2DM especially in urban (22.9%) 
compared to rural (9.9%) areas, which may, in part, be the aftermath of previously 
undiagnosed and unmanaged HIP (Masaki et al.,  2015). This is because screening and 
management for HIP are not commonly practiced in ANC in Tanzania.  As the progression of 
HIP to T2DM may augment the T2DM prevalence (Zhu & Zhang, 2016), HIP (GDM and 
DIP) and its determinants need attention to avert future health impacts.  
1.3  Rationale of the study 
Screening for HIP is an important step for management however, it has received little 
attention in Tanzanian  ANC guideline  as compared to  HIV/AIDS, malaria and tuberculosis 
(Ramaiya et al., 2018) which may be attributed by limited resources. This creates a need for 
developing a simple selective method with less costs for screening and managements of HIP. 
It is therefore, important to recognize that, countries opt for their own diagnostic and 
management criteria due to resource constraints and applicability in their settings. Some 
guidelines recommend universal screening by oral glucosetolerance test  (OGTT) and or 
fasting blood glucose test for all pregnant women (WHO, 2013) while others exempt low risk 
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women from testing (ADA, 2010). There is lack of evidence on how universal strategies 
improve maternal/child health compared to selective strategies, given the increase in 
associated costs, clinician workloads, and potential inconveniences (Farrar et al., 2017). 
Hence, the design and implementation of programs to screen and manage HIP need to be 
determined by individual countries, considering their differences in glucose intolerance, 
competing priorities, resource availability and gaps. 
Several selective screening strategies have been developed in different settings and 
population groups for detection of undiagnosed diabetes and identification of women at risk. 
However, most strategies have been developed in Caucasian and Asian populations (Naylor 
et al., 1997; Caliskan et al., 2004; van Leeuwen et al., 2010; Teede et al., 2011; Sweeting et 
al., 2017) with few based in African populations (Fawole et al., 2014; Adam & Rheeder, 
2017; Nombo et al., 2018). The developed risk scores cannot be generalized due to 
differences in methods used to identify risk factors which vary across countries depending on 
the research design, selection of participants and diagnosis criteria used (Adam & Rheeder, 
2017). In addition, risks for HIP varies within and across settings due to differences in body 
composition, lifestyle, health care systems and genetic predisposition among certain high-risk 
racial/ethnic groups (Kim et al., 2013; Tarquini et al., 2014).  
Furthermore, most selective strategies do not consider body fat percentages which is simple 
to measure for assessing nutritional status during pregnancy compared to pre-pregnancy  BMI 
and or weight gain which depends on an individual’s ability to recall her pre-pregnancy 
weight and early starting of ANC. The previous risk score developed in Tanzania inluded mid 
upper circumference (MUAC) ≥ 28 cm, previous stillbirth, and family history of T2DM as 
significant risk factors for GDM, calling for further development of a tool that involves more 
risk factors such as maternal age, macrosomic delivery, pre-pregnancy BMI, hypertension 
and pregnancy weight gain (Nombo et al., 2018).  
This study therefore, aimed to establish the prevalenc of HIP, IR and associated risk factors 
to develop a risk score which can be simplified into a cheklist for Tanzania’s ANC setting. 
This can be applied during regular ANC education to enable high risk women understand 
their condition, to take responsibility of visiting their health practitioners on their own 
initiative and alter their lifestyles including; poor dietary intake and low physical activities 
(Koning et al., 2016).  
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1.4  Objectives 
1.4.1  General objective 
To determine the prevalence of hyperglycemia in pregnancy, insulin resistance, their 
determinants and knowledge gaps, as well as develop a simplified method for identification 
of pregnant women at risk of gestational diabetes mellitus in Arusha Urban, Tanzania. 
1.4.2  Specific objectives 
(i) To determine the prevalence of hyperglycemia in pregnancy among pregnant 
women attending selected ANC sites in Arusha Urban.  
(ii) To assess risk factors associated with hyperglycemia in pregnancy among pregnant 
women attending select ANC sites in Arusha Urban.  
(iii) To determine the prevalence of insulin resistance among pregnant women attending 
selected ANC sites in Arusha Urban. 
(iv) To assess the determinants of insulin resistance among pregnant women attending 
selected ANC sites in Arusha Urban.  
(v) To assess knowledge regarding hyperglycemia in pregnancy among pregnant       
women attending selected ANC sites in Arusha Urban. 
(vi) To develop a risk score for selective screening of pregnant women at risk of      
gestational diabetes mellitus in selected ANC sites in Arusha Urban. 
1.5  Research questions  
(i) What is the prevalence of hyperglycemia in pregnancy and its associated factors 
among women in Arusha Urban?  
(ii) What is the prevalence of insulin resistance and its relationship with hyperglycemia in 
pregnancy among pregnant women in Arusha Urban? 
(iii) What is the level of knowledge on hyperglycemia in pregnancy among pregnant 
women in Arusha Urban? 
10 
(iv) Which risk factors were included in the model and how many women with GDM 
were identified using risk scores in Arusha Urban? 
(v) What is the performance of the risk score in identification women at risk of GDM 
compared to fasting, urine and OGTT methods in Arusha Urban? 
1.6  Significance of the study    
The study determined prevalence of HIP (that is GDM and DIP) among women attending 
ANC in Arusha, Tanzania and developed a risk score which was simplified into a checklist 
for rapid identification of women with or at risk of GDM. The developed checklist can help 
in selective screening to give priority to the high-risk women when resources are limited 
while improving evidence-based treatments and practices in Tanzania. The study also 
established the prevalence of IR and provided information on the level of HIP knowledge 
among pregnant women in Arusha. This helps to build knowledge of HIP in Tanzania to 
prevent poor pregnancy outcomes and mitigate associated long-term health effects. This 
approach provides evidence to the policy makers to potentiate future application in the 
country for appropriate and cost-effective interventions for testing HIP and provision of 
knowledge for enhancing self-care to improve management. 
1.7  Delineation of the study 
This cross sectional study was done to establish the prevalence of hyperglycemia in 
pregnancy (HIP) to include both gestational diabetes mellitus (GDM) and diabetes in 
pregnancy (DIP) as well as insulin resistance (IR) and their associated risk factors. These 
helped to develop a simplified selective screening strategy for early identification of pregnant 
women at risk of GDM to give priority to high risk women for proper use of limited 
resources.  
Knowledge on HIP was also assessed to understand the gaps for evidence based intervention 
to be planned to enhance self-care among pregnant women. The study covered urban areas of 
Arusha City with high prevalence of type 2 diabetes mellitus which may be partly attributed 
by undiagnosed and unmanaged HIP. The study involved 468 randomly selected pregnant 
women at second and third trimesters, attending ANC at Kaloleni and Ngarenaro health 




2.1  An overview of the study   
Hyperglycemia in pregnancy is a public health problem that affects a significant portion of 
the population. The incidence of HIP increases in the presence of identifiable predisposing 
factors and, concomitantly decreases in the absence of risk factors, suggesting selective 
screening to be a cost-effective option in population health determination (Ben-Haroush et 
al., 2003). Higher prevalence of HIP in women with at least one risk factor compared to the 
general population implies that selective screening and/or counselling of high-risk groups 
could be a better option in sub-Saharan Africa due to limited resources. However, the use of 
selective screening needs to establish a simple, suitable and acceptable strategy for 
identifying women at risk in sub-Saharan Africa (Mwanri et al., 2015). Hence, Tanzania, as a 
resource-constrained sub-Saharan country, needs a simple to apply with less cost method for 
early identification and management of GDM to prevent its short- and long -term effects to 
the mother and her newborn.     
2.2  Etiology of hyperglycemia in pregnancy in forms of gestational diabetes mellitus 
During a normal pregnancy, the mother’s body undergoes a series of physiological changes to 
support the demand of the growing fetus including; adaptation of the cardiovascular, renal, 
hematologic, respiratory, and metabolic systems. An important metabolic adaptation is 
insulin sensitivity, which changes in accordance with varying needs over the course of 
pregnancy. During the early gestational stage, insulin sensitivity increases, promoting the 
uptake of glucose into the adipose stores to prepare for the future energy demands of the 
pregnancy however, as pregnancy proceeds, placental hormones promote a state of IR (Di-
Cianni et al., 2003; Catalano et al., 1991).  
Hence, pregnancy is associated with IR and hyperinsulinemia which may predispose women 
to develop GDM (Alfadhli, 2015). Insulin resistance during pregnancy is the inability of a 
defined concentration of insulin to affect an expected biological response of nutrient 
metabolism at the level of the target tissue, which result from increased maternal adiposity 
and insulin-desensitizing effects of placental hormones (Lain & Catalano, 2007; Buchanan & 
Xiang, 2005). This occurs when pancreatic β-cells are unable to produce sufficient insulin to 
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offset IR which starts near mid-pregnancy and persists in the third trimester to levels similar 
to T2DM individuals (WHO, 2013; Buchanan & Xiang, 2005). If IR becomes dominant, the 
women develop hyperglycemia with IR increasing progressively until delivery, when it often 
quickly disappears in most cases (Ben-Haroush et al., 2003).  
As pregnancy progresses, the production of placental hormones, such as estrogen, 
progesterone, cortisol, and lactogen also increases, hindering the functions of insulin and 
gradually reducing insulin sensitivity to 50% of the expected value (McLachlan et al., 2006). 
These placental hormones cause enlargement of the islets of Langerhan cells and/or the 
hyperplasia of the pancreatic β-cells (Ramiya et al., 2000) to increase the secretion of more 
insulin, resulting in compensated hyperinsulinaemia (Ryan et al., 1985).   
In addition to placental hormones, many metabolic changes during pregnancy increase 
adipose tissue which produces numerous adipocytokines which can act as hormones involved 
in regulation of maternal metabolism and gestational IR like adipokines (tumor necrosis 
factor [TNF]-alpha and leptin).  These can impair insulin signaling which leads into to IR 
condition (Wiznitzer et al., 2009; Retnakaran et al., 2009; Palani  et al., 2014). Insufficient 
insulin secretion to offset the decreased insulin sensitivity may result in development of 
GDM (Palani  et al., 2014).  
The fasting plasma glucose, leptin, progesterone and cortisol significantly increase, as 
evidenced by pregnant women who develop GDM as the rate of insulin-stimulated glucose 
uptake is reduced by up to 54% in GDM affected women (Ngala et al., 2017; Catalano, 
2014). As GDM and T2DM share a similar genetic background,  and IR represents an 
important risk factor for T2DM (Kwak et al., 2012), screening for IR can be a strategy for 
identifying high-risk women for appropriate actions to be taken to prevent GDM and T2DM. 
With this association, there is a need to establish the prevalence of HIP and IR, given the high 
prevalence of T2DM that is reported in urban areas of Arusha Region (Masaki et al.,  2015). 
2.3  Risk factors for insulin resistance and hyperglycemia in  pregnancy    
Hyperglycemia in pregnancy is related to potential risk factors such as history of stillbirths, 
high parities, MUAC > 28 cm, family history of diabetes, advanced maternal age, and 
overweight/obesity (i.e., BMI > 25 kg/m2) (Asare-anane et al., 2014; Buhling et al., 2004; 
Mwanri et al., 2014).  Most women with GDM are obese however, those who are not obese 
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by traditional weight criteria may have an increased percentage of body fat distributed 
predominantly in the abdominal region which increases the risk of GDM (ADA, 2010).  
Pregnancy is associated with increased maternal adiposity and storage of carbohydrate and 
fat, possibly as an evolutionary adaptation to facilitate successful lactation. If body fat 
accumulation becomes excessive, it may cause diabetes mellitus, high blood pressure, or 
other complications during pregnancy (Ay et al., 2009). Studies on people with T2DM have 
identified that, fat deposition within skeletal muscle and liver cells is a major contributory 
factor to IR but, it is not well explored on whether fat deposition during pregnancy explains 
the development of IR (Ravikumar et al., 2005).  
Pregnancy BMI reported as degrees of overweight or obesity is a commonly used indicator to 
determine nutrition status in pregnancy; though, it does not distinguish between fat and lean 
body mass (Kotnik & Golja, 2012). In addition to late staring of the ANC, most women start 
their pregnancy without knowing their weights, making it difficult to estimate their BMI and 
weight gain during pregnancy which is strongly correlated with fat mass change (Berggren et 
al., 2016). Measuring body fat content is very important because, in addition to fat and lean 
body mass, the fetal mass and amniotic fluid represent unknown contributions to  the total 
body mass, which are not distinguished by BMI calculation (Fakier,  et al., 2017). However, 
more exploration of the appropriate stage in pregnancy at which body fat percentage can be 
estimated is needed.  
Monitoring a total weight gain could be a good indicator and simple to determine but, it is 
based on the pre-pregnancy BMI which also relies on ability of the pregnant women to recall 
her pre-pregnancy weight. Weight during pregnancy can also be estimated before 16 weeks 
of gestation which depends on early initiation of the first ANC visit (Institute of Medicine 
[IOM], 2009; Siega-Riz et al., 2009), but is often impractical in Tanzania’s ANC context  
where most of the women  cannot recall their pre-pregnancy weights and start the first ANC 
visit late (Mwanri et al., 2014). The delayed start of the first ANC visit is one of the 
challenges in FANC guideline implementation in Tanzania where only 20% of women 
attended their first ANC visit during the first trimester of pregnancy (Kearns et al., 2014).  
Dietary intakes before and during pregnancy can influence glucose level of the woman 
(Macaulay et al., 2014), which depends on the type of food and nutritional contents. High 
glycemic index (GI) foods, including rice, white bread, and potatoes, cause a sharp rise in 
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blood glucose levels which decline rapidly.  On the other hand low GI foods; such as fruits or 
dairy products, introduce slowly digestible carbohydrates which result in a lower postprandial 
glucose response (Brouns et al., 2005; Zhang et al., 2006). There is a significant positive 
associations of maternal dietary heme iron intake with the risk of  GDM potentially due to the 
predominant heme-iron contribution from animal sources, including red meat and poultry 
which are also increasing the effects of fat accumulation hence HIP (Qiu et al., 2011).  
Some vitamin deficiencies may increase the risk of HIP, such as Vitamin D which is a fat-
soluble hormone known to play a role in maintaining calcium homeostasis and bone integrity 
including its role in glucose metabolism, angiogenesis, inflammation and immune function. It 
also regulates gene transcription and expression (Mousa et al., 2015) however, micronutrients 
assessments need more resources for laboratory analysis. As they can simply be included in 
dietary counselling, there is no need of including them in screening strategies.   
Advanced maternal age is an established risk factor for GDM, and may be a result of age-
related changes, which are particularly characterized by an impaired response to glucose 
challenge, which is partly due to physical inactivity and a decrease in muscle mass. This may 
have a similar effect on IR in pregnant women, which needs more exploration (Kuo et al., 
2017). Studies done in Bangladesh and India have reported that, the odd of GDM is 
increasing with age > 25 years (Begum et al., 2017; Seshiah et al., 2008).  
Family history of T2DM has been reported as a potential determinant for GDM in several 
studies in Africa and outside Africa (Asare-anane et al., 2014; Nombo et al., 2018). The 
influence of T2DM on development of GDM may be due to genetic predisposition as a result 
of belonging from high-risk racial/ethnic groups (Tarquini et al., 2014). This have been 
reported in Bangladesh that, 74.4% of the GDM patients had family history of DM compared 
to 39.1% among normal pregnant women (Monir et al., 2018). This shows how family 
history of diabetes contributes highly in the development of GDM. Hence, early identification 
of these women even before pregnancy could help to lower the risk of developing GDM and 
later on T2DM through controlling of their lifestyles (Monir et al., 2018).  
The association between parity and diabetes is strongly linked to obesity and age. Women 
with higher parity normally are older and more obese (Dode & dos Santo, 2009). Obesity is 
an intermediate outcome in the causal pathway between parity and GDM, possibly a 
facilitating factor; however, age is a potential confounder in the relationship between parity 
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and GDM (Dode & dos Santo, 2009). Likewise, parity is not directly linked to insulin 
sensitivity deterioration, to fasting plasma glucose increase during pregnancy, or to the 
occurrence of GDM, though it is linked through the mediation of progressive ageing and 
weight gain either before or during pregnancy (Seghieri et al., 2005). 
Preeclampsia is defined as a new onset of hypertension with blood pressure consistently > 
140/90 mmHg in previously normotensive women and new onset proteinuria (defined as > 
300 mg per 24 hours or > 2+ by dipstick) occurring after the 20th week of gestation 
accompanied by the presence of edema (American College of Obstetricians and 
Gynecologists [ACOG], 2003). Insulin sensitivity in late normal pregnancy is 45% to 70% 
lower than that of non-pregnant women; however, it plays a major role in T2DM 
development and in the pathogenesis of hypertension, dyslipidemias, and coronary artery 
diseases (Cunningham et al., 2010; ACOG, 2003). Almost all obese women with 
hypertension have elevated insulin and the highest levels occur in obese women with 
excessive abdominal adipose tissues (Cunningham et al., 2010; ACOG, 2003).  
Also, in pregnant women, obesity is a consistent risk factor for preeclampsia. Insulin 
resistance may lead to hypertension by changes in the levels of intracellular sympathetic 
nervous system over activity and renal sodium retention (Kaplan, 1994). Maternal mid-
trimester IR increased significantly with increasing BMI and subsequent preeclampsia which 
is a combination of hypertension, proteinuria and edema (Hauth et al., 2011). Women who 
develop preeclampsia have higher insulin levels before clinical evidence of disease than 
women who remain normotensive during pregnancy (Malek-Khosravi & Kaboudi, 2004). 
This creates a need for early identification of women at risk of the conditions for appropriate 
interventions to prevent short- and long-term health effects to the mother and her newborn.  
Increased maternal adiposity, as a result of high fat accumulation and placental hormones, is 
attributed to insulin-desensitizing effects which lead to gestational insulin resistance. 
Additionally, both increase pre-pregnancy BMI and weight gain during pregnancy are 
positively associated with gestational insulin resistance and obesity is a risk factor for GDM 
(Catalan et al., 1998; McIntyre et al., 2020).  
2.4  Knowledge of hyperglycemia in pregnancy among pregnant women  
Hyperglycemia in pregnancy is increasing in different parts of Sub-Saharan Africa including 
Tanzania. Despite the increasing prevalence of HIP and its effects, the majority of the 
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pregnant women, and other community members may be unaware of its existence, risk 
factors, and its associated consequences which may delay diagnosis, prevention and 
management. As knowledge is an important component of health literacy, insufficient 
knowledge about any disease leads to poor understanding of medical information limiting 
adherence to management strategies and, in the case of GDM, may contribute to adverse 
pregnancy and post-natal outcomes (Koning et al., 2016; Baker, 2006). Adequate knowledge 
about HIP will potentiate opportunities to adopt healthier lifestyles and better healthcare-
seeking patterns (Elamurugan & Arounassalame, 2016).  
This needs attention from healthcare providers to raise awareness among pregnant women as 
undiagnosed and unmanaged GDM may subject the women and newborns to increased health 
effects (Staynova et al., 2017; Lehnen et al., 2013). A study done in Ghana showed a 
significant relationship between knowledge and risk factors which implies that the higher the 
level of knowledge on GDM and on its risk factors leads to proper management and lastly 
better outcomes  (Azu & Essel, 2017). Another study done to assess the perceived risk of 
GDM using theoretical models of risk perception found that, women who had greater 
perceptions of risk, more often intended to improve their behavior in the future (Kim et al., 
2007). Another study reported that, having a higher 2 hours OGTT value in pregnancy was 
associated with higher rates of return, since women are generally aware of the risk of 
developing T2DM after having a GDM diagnosis (Zera et al, 2013).  
In Tanzania, there is limited evidence regarding knowledge about HIP, which leads to a 
research imperative to assess knowledge among pregnant women. It is important to 
understand that, knowledge on a disease and its consequences can lead to behavior change as 
it makes an individual to understand or become aware of the condition, its effects and 
prevention strategies. Therefore, a person can take actions accordingly to prevent the 
occurrence of the condition, leading to a new behavior development. This can be explained 
by behavior change model which demonstrates how knowledge may cause an individual to be 
aware on different aspects of the condition and decide to take actions to change behaviors 
accordingly (Fig. 1). 
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Figure 1: General behavior change model (Hungerford & Volk, 1990) 
The interaction between knowledge and behavior change can be explained well by the Health 
Belief Model (HBM) (Irwin, 1974; Janz & Marshall, 1988). The HBM is a cognitive model 
suggesting that, behavior is determined by beliefs about threats to an individual’s well-being, 
as well as the effectiveness and outcomes of particular actions or behaviors (Irwin, 1974; 
Janz & Marshall, 1988). This model was developed to understand the reasons for failure of 
people to adopt disease prevention strategies or screening tests for early detection of disease, 
which relates much with the current study.  
The HBM explains that, after having knowledge of the condition, behavior change occurs 
when people feel to be personally vulnerable to the health threat or condition, and view the 
possible consequences of the condition as severe. People must see that, taking action may 
either prevent or reduce the risk at an acceptable cost with few barriers. In addition, a person 
must have self-efficacy to execute and maintain the new behaviors (Irwin, 1974; Janz & 
Marshall, 1988) (Fig. 2). At this point, internal and external factors are required to ensure that 
the acquired behavior is maintained. These factors may include different sources of 
information such as media, relatives, family and in the case of pregnant women, the regular 
ANC education program can be an external factor. 
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Figure 2: The health belief model (Irwin, 1974; Janz & Marshall, 1988) 
2.5  Methods of screening  for gestational diabetes mellitus  
Timely diagnosis of GDM is the first step towards effective management and prevention of 
adverse outcomes however, the case detection of GDM in sub-Saharan Africa remains sub-
standard (Macaulay et al., 2014; Mwanri et al., 2015). The WHO has adopted the criteria 
developed by the International Association of Diabetes and Pregnancy Study Group 
(IADPSG) for the diagnosis of GDM which recommends universal screening of all pregnant 
women using OGTT and/or fasting blood glucose test (Metzger  et al., 2010; Wendland et al., 
2012).  
The use of OGTT and/or fasting blood glucose test may also be a good approach but has 
limited applicability for GDM screening in resource constrained sub-Saharan Africa where 
the testing requirements are prohibitive and/or inconvenient for the women who must travel 
long distances, for ANC in fasting state and incur additional transport costs (Ntui et al., 2013; 
Mrisho et al., 2009). Moreover, women who are not informed during an earlier visit or forget 
to come in fasting state, require a successive visit for the test. Several samples are required 
for glucose testing which becomes a burden to the woman and healthcare personnel (Agarwal 
et al., 2011). The associated costs for IADPSG testing standards are unaffordable by the 
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majority of low-income clients and the method requires women to stay at the ANC for more 
than two hours without eating (Agarwal et al., 2011; WHO, 2013). 
On the other hand, universal screening by using fasting serum insulin can be a sensitive 
method because the main mechanism for HIP is dysfunction of pancreatic beta cells, 
manifesting in IR during pregnancy (Reece et al., 2009). Hence, this indicator could be a 
helpful parameter in individualization of treatment and early prevention of complications, but 
it is very expensive compared to other methods and often not applicable to scarce resource 
settings. 
A formal risk assessment for GDM could be undertaken at the first prenatal visit and for the 
women with high risk of GDM with clinical characteristics, such as obesity, personal history 
of GDM, glycosuria, advanced maternal age, strong family history of IR and/or diabetes 
should undergo glucose testing as soon as feasible (Plows et al., 2018; ADA, 2010). It may 
not be a proper use of limited resources to screen women at low risk, such as < 25 years of 
age, normal body weight, no family history of diabetes or abnormal glucose metabolism, and 
no history of poor obstetric outcome (ADA, 2010).  
A risk score can be used  in limited resources, but accurate identification of risk factors may 
be difficult. This made FANC to change from the traditional risk identification with more 
numbers of ANC visits, due to high or nearly similar costs to the existing model. However, 
the current FANC is still facing challenges in implementation of its guideline in Tanzania’s 
ANC due to limited resources (Kearns et al., 2014). This may have contributed largely to 
poor consideration of GDM screening and management in the guideline as extra resources 
may be required following the costs associated with the recommended universal screening by 
OGTT and/or fasting glucose tests (WHO, 2013).  In this case, the available resources can be 
used to high risk women while planning for universal testing. Hence, due to limited 
resources, risk score can be simplified into a factors checklist which can be easily understood 
by health care workers and women of reproductive age for self-identification and care. This 
approach could provide a simple and easily up taken intervention that will articulate with 
plans for universal screening.  
Although many risk scores have been developed in different settings, the establishment of a 
scoring system should be country specific due to differences in the levels of fat adiposity, 
glucose intolerance, and ability to cover the associated costs (Kim et al., 2013; Farrar et al., 
20 
2017). To be more effective, the developed risk scores should be simplified for easy of 
interpretation and application by the health care providers and women themselves to promote 
self-care among pregnant women. 









MATERIALS AND METHODS 
3.1  Description of the study area 
Arusha Region is one of Tanzania's 31 administrative regions with a total population of 1 694 
310 (NBS, 2013). The capital city of Arusha has a total population of 416 442 plus 323 198 
people living in Arusha District (NBS, 2012). The region is bordered by Kajiado and Narok 
County in Kenya to the North, Kilimanjaro Region to the East, Manyara and Singida regions 
to the South, Mara and Simiyu Regions to the West. Arusha Urban (City Council) is one of 
the seven districts of the Arusha Region which is bordered to the South, West and North by 
Arusha Rural District and to the East by Meru District (Fig. 4).  
The city has 6 hospitals, 15 health centers, 64 dispensaries and 25 specialized facilities. 
Among these facilities 56 have ANC of which 24 has both ANC and delivery services. The 
city has a total number of 26 167 pregnant women who started first ANC visits in 2018 
(District Health Information System [DHIS], 2018). The study was conducted in two health 
centers with a total number of 10 422 pregnant women who started first visits in 2018 (DHIS, 
2018). 
Figure 4: Arusha map indicating the study area (NBS, 2012) 
 
Study area  
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3.2  Study design  
This was a cross-sectional study that was conducted in urban areas of Arusha City between 
March and December 2018. This involved pregnant women attending ANC at Ngarenaro and 
Kaloleni Health Centers. These centers were selected among 24 health facilities which offer 
both, ANC and delivery services. The two centers have a total of 10 422 out of 26 167 
pregnant women which is about 40% of all women who started their first ANC visit in 
Arusha City (DHIS, 2018). Two centers were purposive selected due to their central location 
in the district, and enabling services reach for the largest number of pregnant women.  
3.3  The study population  
3.3.1  Inclusion criteria 
The study included pregnant women at the second and third trimesters between 24-36 weeks 
of gestation as HIP is defined as any glucose intolerance that is first detected at any time 
during pregnancy (ADA, 2018; WHO, 2013).   
3.3.2  Exclusion criteria 
The study excluded pregnant women with diabetes before pregnancy and are under- diabetes 
management or treatments. All women who were unwilling to participate or provide consent 
were excluded from the study.  
3.4  Sample size determination 
Eligible women were selected with assistance of the nurses’ in-charge at each participating 
site until a total of 468 women were recruited to the study. This sample size was obtained 
using the formula for prevalence studies (Daniel, 1999):  
                                                                  n = [z2*p*q]/d2 
Where: n = desired sample size  
 Z = standard normal deviation set at 1.96 corresponding to 95% CI              
q = 1.0 – p   
d = degree of accuracy desired (0.05) 
p= proportion of the target population with HIP        
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Due to limited national data for prevalence of HIP (GDM and DIP), and the assumption of a 
high risk of HIP for a transitioning urban population, p = 50 % was used as the prevalence to 
capture the maximum reality (MacFarlane, 1997). The response rate was assumed to be 78%; 
yielding a consideration of 20% non-respondent rate. The percentage for non-response was 
set due to the experience from a study done in Kilimanjaro where the rate of loss to follow up 
for the subsequent testing was > 20% (Njete et al., 2018).  
3.5  Sampling techniques   
Purposive sampling was employed to obtain one district located in urban area out of seven 
districts of Arusha Region.  Two ANC centers (Ngarenaro and Kaloleni) were purposively 
selected from the 24 facilities with both ANC and delivery services due to the large number 
of pregnant women (40%) accessing ANC services from across the District in 2018. 
Proportionate sampling was used to select pregnant women from the two ANCs to ensure a 
total of 468 respondents where by 31% of the pregnant women were selected from Kaloleni 
and 69% from Ngarenaro. These women were stratified by age (< 25 years and ≥ 25 years of 
age) to avoid the selection of women from one age category which might be at low or high 
risk only. Random selection using a table of random numbers was done to obtain 468 
pregnant women who met the inclusion criteria. Due to high number of women attending 
ANC per day, a maximum of 12 pregnant women were selected per day. Among the 468 
pregnant women who were sampled, half of them were randomly selected for IR testing 
whereby 230 pregnant women were included while four women were excluded as their blood 
samples coagulated before laboratory tests were performed.   
3.6  Data collection and laboratory analysis 
3.6.1  Training of the research assistants and pretesting of research tools  
Before the actual data collection processes, nurses and research assistants who were 
nutritionists with enough experience on human research, were trained on the study protocol 
and how to use the research tools. The training was done for five days using English and 
Kiswahili language and the questionnaire was translated to Kiswahili as well. After the 
training, all trainees were involved in pretesting the tools with 20 randomly selected women 
from Ngarenaro health facility who were not part of the study and the resultant data was not 
included in the actual study. The pre-test results were discussed, and appropriate changes 
were made to improve the research tools (Appendix 1).   
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3.6.2  Recruitment and overall data collection procedure  
The study was introduced to pregnant women who met the selection criteria. A total of 500 
pregnant women were recruited of which 94% (n=468) consented to participate in the study. 
The remained 6% (n=32) of the pregnant women could not consent after explanation of the 
whole data collection procedure including, harms and benefits of participating in the study. 
These women complained on the costs that may arise if several visits would be required for 
subsequent testing. They also complained on the long time that is required to complete all 
data collection procedure especially the OGTT which required women to stay in the facility 
for more than two hours.   
After women have consented, those who come while fasting were tested for fasting plasma 
glucose and performed the OGTT procedure in the same day. During assessments half of the 
women in each day were randomly selected from the same group for venous blood samples 
collection to test for IR. Selected women were also interviewed in the same day to reduce 
transport costs. Women who consented but came while eaten food, were requested to come 
the next day while fasting for 8-12 hours where all the assessments would be done. These 
women were given a tag with the number of researchers for confirmation on the exactly day 
of retuning to avoid taking large number of women in a day. Majority of the women who 
were selected and agreed to come another day for assessments, were requested to go back 
home without performing their regular ANC assessments so that they can be served when 
they return to participate in the study. In this way loss for follow- up tests was minimized.  
During the assessments, women started with fasting glucose test, followed by urine and 
venous blood samples collection. Thereafter, women were provided with 75 g of glucose 
powder dissolved in 300 ml of clean water to test for OGTT. Disposable cups were used for 
drinking glucose solution to avoid sharing of utensils. Women were requested to finish 
drinking their solution within five minutes.  For time management after glucose consumption, 
each woman was given a tag which indicated the time at which glucose was consumed and 
the time for the second test. Their names and times after glucose consumption were recorded 
by the researchers for reminder.  
During the two hours waiting for OGTT testing, interviews and other assessments, such as 
anthropometric measurements, and normal ANC services were conducted. This helped to 
minimize time for commitment and encourage compliance. All pregnant women with high 
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fasting glucose levels (≥ 5.1 mmol/L) were requested to come for another fasting test in the 
next day or within a week to confirm. After confirmation, all women with HIP were advised 
and refereed to the doctor for further actions to be taken. After referrals, all pregnant women 
with HIP were followed up through phones to know their progress and provide them with 
advices accordingly (Fig. 5). 
Figure 5: Flow chart for recruitment and data collection procedure   
3.6.3  Assessment of demographic characteristics and selected risk factors for 
hyperglycemia in pregnancy  
Recalled information with respect to weight before pregnancy, previous birth modalities 
(caesarian section or normal delivery), family history of T2DM, previous history of GDM, 
symptoms of T2DM, and previous delivery to babies with ≥ 4 kg at birth (macrosomic) were 
collected through face-to-face interviews using a questionnaire with structured questions 
(Appendix 1).  
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Other clinical and maternal characteristics, such as age, previous history of stillbirth, neonatal 
death, gravidity, education level, occupation, marital status, and weight during the first 
antenatal visit were obtained from the participants’ ANC records and confirmed by the 
women through face to face interviews. Gestational age was estimated using the last 
menstrual period as reported by pregnant woman during her first ANC visit and for those 
who could not remember their last menstrual period, ultrasound assessment was conducted.  
3.6.4  Laboratory assessments for hyperglycemia in pregnancy and insulin resistance  
            among pregnant women 
(i)  Blood samples collection 
The fasting capillary blood samples were taken using a finger prick with a sterile lancet after 
cleaning the site with an antiseptic alcohol swab. Additionally, 5 mls of fasting venous blood 
was taken from 50% of the randomly selected participants using a sterile syringe and drawn 
out of the syringe into vacutainer tubes containing no anticoagulant. Venous blood samples 
were stored in a cool box and transported to the Nelson Mandela African Institution of 
Science and Technology laboratory to analyze insulin concentrations for determining IR.   
Urine samples were also collected using disposable hospital urine sample containers (60 ml) 
in the morning and tested for glucose and protein  The fasting capillary blood samples were 
tested for glucose within five  minutes after drawn and 2 hours followed the consumption of 
glucose solution.  
(ii)  Test for hyperglycemia in pregnancy 
Fasting blood glucose and OGTT were tested using Gluco-plusTM (Glucoplus Inc. 2323 
Halpern, Ville St. Laurent, Quebec, Canada). The capillary plasma glucose values obtained 
were converted to venous plasma glucose using the regression equation developed for 
diabetes screening in the low resource areas where venous blood test is challenging 
(Bhavadharini et al., 2016). Women with fasting blood glucose levels ≥ 5.1mmol/L were 
requested to return the next day for another fasting glucose test. All women with < 7 1 
mmol/L were requested to consume 75 g of glucose dissolved in 300 ml of water and stayed 
for 2 hours without eating, after which capillary blood was measured for levels of plasma 
glucose (WHO, 2013).  
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Women were classified as having HIP if they met the criteria for either DIP and/or GDM.  
Women with GDM were classified as having fasting plasma glucose (5.1-6.9 mmol/l (92 -
125 mg/dl), or a 2-hour plasma glucose (8.5-11.0 mmol/l (153 -199 mg/dl) following a 75-
gram oral glucose load. In addition, women with DIP were classified by fasting plasma 
glucose ≥ 7.0 mmol/l (126 mg/ dl) and/or 2-hours plasma glucose ≥ 11.1 mmol/l (200 mg/dl) 
following a 75 g oral glucose load  (WHO,  2013). Urine samples were tested within one hour 
using multi-sticks with color sensitive pads (Urine strips 388-25, Gomo-ro, Gimhae-si, 
Gyeongsangnam-do, 621-881, Korea). All women identified with HIP were referred to the 
doctor for further actions and follow-up were done through phone calls, messages and 
physically during their ANC visits. 
(iii)  Tests for insulin resistance  
Serum was obtained by centrifuging (Eppendorf Centrifuge 3500R) the blood sample for 15 
minutes, separated from clot by pipetting the supernatant into vials, and stored in the 
refrigerator at -80˚C before analysis (Tuck et al., 2009). Serum insulin concentrations were 
measured using a Synergy/HTXTM (BioTek instrument, Inc. Highland Park Winooski, VT 
05404-0998, USA) machine with Human Serum Crystal ChemTM (Crystal Chem Inc. Elk 
Grove USA) high performance assays as explained in the procedure below.  
(iv)  Preparation of reagents according to the manufacturer’s instructions 
(a) The instruction manual from the ELISA kits manufacturer was read, discussed, 
and well understood by the researcher and the laboratory technician before the 
actual analysis (Fig. 6). 
(b) The antibody-coated micro plate was provided as ready to use.   
(c) The standards were provided by manufactures in lyophilized form and diluted by 
1.0 ml of de-ionized water. This involved 1-6 standards in the concentrations of 
(0, 3, 10, 30, 110 and 220 mU/L) which sat for 5 minutes at room temperature and 
then were mixed gently to dissolve all solid particles.  
(d) The controls provided were also diluted by 1.0 ml of de-ionized water, allowed to 
sit for 5 minutes at room temperature and then mixed gently to make all solids 
dissolve. These were provided in the concentration of 13:150 mU/L. 
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(e) The provided HPR binding labeled antibody was also diluted in the ratio of 1:12 
using a provided ready to use diluent and mixed thoroughly. 
(f) The wash buffer provided was 30x concentrate requiring dilution with distilled 
water in ratio of 1:30 (i.e., 50 ml were diluted by 1450 ml of distilled water).  
(g) The substrate and stop solutions were provided as ready to use.  
Figure 6: Internalizing the instruction manual for preparation of analytical reagents 
 (v)  Assay procedure (aliquot) 
(a) Before running the assay, all reagents and samples were brought to room 
temperature to sit for 5 minutes and then introduced in the VortexTM (mixer) for 
thorough mixing. 
(b) The samples were run in duplicate.  
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(c) In each well of the antibody-coated micro plate, a 100 µl of HPR labeled antibody 
solution was added followed by 25 µl of the sample, standard, control and mixed 
well by repeated pipetting. 
(d) The wells were covered with a plate sealer and incubated for 2 hours at 37 0 C.  
(e) The contents were well aspirated and washed three times in an AccuwashTM 
machine using 300 µl of wash buffer per well.  
(f) After washing, 100 µl of substrate solution was added in each well and incubated 
for 15 minutes at room temperature in a dark place.  
(g) The reaction was stopped by adding 100 µl of the stop solution (Fig. 7).  
(h) The plates were placed in a Biotech biosciences Synergy/HTXTM ELISA machine 
and absorbance were measured within 30 minutes using a plate reader (measured 
at A450 and A630 values) and mean difference was obtained (Fig. 8).  
(i) A computer software was used to construct the insulin calibration curve by 
plotting the mean change in absorbance values for each calibrator on the Y-axis 
versus the corresponding insulin concentration on the X-axis. This formed a 
typical standard curve with equation for calculating insulin concentration in each 
plate (Fig. 9).  
(j) From the above standard equation, that is Y=0.013x -0.0566, the concentrations 
for each sample in a plate (represented by X) was calculated given the values of Y 
(Absorbance).  
(k) Then insulin concentration was interpolated using the calibration curve and the 
mean of each absorbance values for each sample and insulin concentration was 




Figure 7: Addition of stop solution to stop the reaction
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Figure 8: A plate placed in an ELISA machine for reading
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Figure 9: The graph for absorbance’s against the standard concentrations 
Lastly, IR was calculated using the Homeostasis Model Assessment (HOMA-IR) formula 
(Matthews et al., 1985) and defined by a HOMA-IR score ≥ 2.5 (Longo-Mbenza et al., 
2011).  
 
3.6.5  Anthropometric assessments  
Mid-upper arm circumference (MUAC) was measured using a non-stretchable standard tape. 
The participant stood upright with the weight evenly distributed on both feet with shoulders 
relaxed, and the arms hanging loosely at the sides. Some studies reported that MUAC may be 
used instead of BMI due to its relative stability during the course of pregnancy and high 
correlation with pre-pregnancy BMI (Fakier,  et al., 2017; Gale et al., 2007). Women were 
categorized as normal with a MUAC of < 28 cm and overweight with MUAC ≥ 28 cm.  
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Weight was measured with minimal clothing and without shoes using a digital bathroom 
weighing scale (SECA-Germany), placed on a flat surface. The participants were requested to 
stand on the center of the scale platform facing the recorder and looking straight ahead. Two 
measurements were taken and recorded to the nearest 0.1 kg.  
Height was measured using a stadiometer (Shorr Productions, Maryland USA) where the 
participant was requested to stand up straight against the backboard with the body weight 
evenly distributed and both feet flat on the platform, with the heels placed together and toes 
apart. The back of the head, shoulder blades, buttocks and heels were made to contact with 
the backboard. The head was aligned in the Frankfort horizontal plane and the stadiometer 
head piece was lowered to rest firmly on top of the participant’s head, with sufficient pressure 
to compress the hair. The measurements were taken in duplicate and recorded at the nearest 
0.1 cm.  
This measured height together with recalled pre-pregnancy weight were used to calculate the 
pre-pregnancy BMI of the women where only 238 pregnant women were able to recall their 
pre-pregnancy weight. Weight during the first visit could not be used to calculate BMI due to 
late initiation of the ANC (usually at 18 weeks gestation as observed in this study). The per-
pregnancy data for calculating pre-pregnancy weight may have shown biases due to either 
over or underestimation during recalling. The pre-pregnancy BMI was calculated by the 
weight of individual in kilogram per meter squares and subject with BMI < 18.5 kg/m2 was 
classified as underweight, 18.5-24.9 kg/m2 as normal, 25-29.9 kg/m2 overweight and ≥ 30 
kg/m2 obese (WHO, 2006).   
Body fat percentage was determined using a bioelectric impedance analyzer (Tanita TBF 105 
Fat Analyzer™), which included adjustments for age, weight, and height (Fig. 10). The body 
fat percentage values were treated as continuous variables due to lack of established 
classification criteria for pregnancy. The presence of edema was also assessed through 




Figure 10: Measurement of body fat percentage 
Blood pressure was measured using a GT-868UF Geratherm™ machine on the left mid-
upper- arm, while the participant was sitting and relaxed for 10 minutes before the actual 
measurement.  Two measurements of blood pressure were done at an interval of five minutes 
and the average was recorded. Blood pressure was classified using the Standard treatment 
guidelines and essential medicines list categories of systolic 140 to 159 mmHg or diastolic 90 
to 99 mmHg (MoHSW, 2013).  
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3.6.6  Assessment of knowledge on hyperglycemia in pregnancy among pregnant 
women  
Knowledge on HIP was assessed using a questionnaire which was administered through face 
to face interviews. Information collected on knowledge included respondents’ views on the 
meaning, symptoms, consequences, and risk factors for HIP. Common practices used to 
screen and manage HIP in their previous pregnancies, such as testing methods, follow up 
after diagnosis, and management practices were also assessed using questionnaire which 
included both closed- and open-ended questions. This information was assessed to know the 
previous experiences of the women on the services provided to get evidence to recommend 
for an intervention. This information helps to understand other sources of health information 
and how knowledge can influence behavior change during implementation of screening and 
management strategies.  Moreover, as the study aimed to develop a tool that can be used by 
both healthcare providers and women themselves, it was important to understand their 
knowledge about HIP for effective implementation of the tool.  
The researchers recorded verbal responses or ticked responses if matched with provided 
alternatives or wrote the response under the ‘others’ option if not matched with the provided 
options. Responses were coded and knowledge was determined by the percentages of women 
who answered the questions correctly. The assessment was done by a research scholar based 
on the responses obtained from the questions. The interpretation of knowledge was done 
based on the scores obtained, that is, those who answered correctly were interpreted as having 
adequate knowledge and were graded with a score of 1 for each question which were then 
converted into percentage. Hence, excellent knowledge was regarded as ≥ 75% correct, good 
knowledge between 51% and 74% correct; average between 26% and 50% as well as poor 
knowledge ≤ 25% (Dhyani et al., 2018).  
3.6.7  Development of the risk scores   
All women with DIP were excluded from the data to develop a risk score for identification of 
women with or at risk of GDM. Variables collected as risk factors for GDM were analyzed 
for descriptive statistics to check for missing data or any abnormal distributions. Cross-
tabulation analysis was carried out to identify relationships among variables for categorical 
data. Variables found to have a relationship with GDM from previous research evidence and 
confirmed by cross-tabulation were entered into a logistic regression model for analysis. 
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Univariate analysis of each variable in relation to GDM was done to assess their individual 
contribution to the development of GDM.  
All variables with a p-value of < 0.05 were entered in a model. Multivariable analysis was 
performed, and the estimated coefficients and p-values were compared with those in the 
univariate analysis, whereby all non-significant predictors (p value > 0.1) were eliminated at 
this stage and a new model with significant predictors was set. Backwards elimination as 
described by Harrell (2015) was used as it starts with a full model (includes all variables) and 
eliminates non-significant variables one by one. 
Performance of the new model was compared with the full model and the process repeated 
until the model contained significant predictors only. For the model to be applicable, each 
risk factor was scored based on the estimated coefficients whereby the increase in number of 
the scores indicated high risk of GDM (Caliskan et al., 2004). The risk scores were 
calculated, indicating the risk factors and their corresponding scores multiplied by ten (10) to 
remove decimals to get integers for easier interpretation and application in ANC settings and 
for individual use. The sum of the score was calculated for each participant by adding the 
score for each significant variable in the risk model and a total GDM risk score was 
calculated as the sum of all individual scores.  
Performance of the model was assessed using discrimination assessment which looked at 
whether estimated risks were different for patients with and without GDM. This was done 
using the c-statistic, known as the area under the receiver–operating characteristics curve 
(AU-ROC) for binary outcomes. This was done with the probability that, a randomly selected 
patient experiencing an event (which is GDM in this case) has a higher predicted probability 
than a randomly selected patient not experiencing the event (Wynants et al., 2017).  
The clinical utility of the model was assessed using the Net Benefit (NB) to obtain the 
threshold for decision making (Wynants et al., 2017). This assessment was conducted based 
on the net proportion of true and false positive values at a selected threshold whereby the 
higher the net benefit for the model the higher the utility of the model.  
3.7  Statistical analysis   
Data collected were entered, cleaned, edited and analyzed using the Statistical Package for 
Social Science™ (SPSS™) Version 20 and R-Test™ version 3.61. 
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3.7.1 Demographic data 
Demographic attributes were assessed using means, percentages, and frequencies obtained 
using SPSS. For example, means, frequency and percentages for maternal age, gestational 
age and income were reported.   
3.7.2  Anthropometrics data 
Percentages were obtained from SPSS to describe the prevalence of overweight, obesity, 
hypertension and edema. Means were calculated for weight, height, MUAC and body fat. The 
comparisons for these continuous variables were done using t-test. 
3.7.3  Prevalence of hyperglycemia in pregnancy, insulin resistance and associated risk  
            factors  
Descriptive statistics were used to obtain percentages for the prevalence of HIP, GDM, DIP, 
and IR. The means were calculated for OGTT, fasting blood plasma and insulin concentration 
values which were compared using the t-test for the women with and without conditions. The 
associations among variables started with descriptive statistics to detect missing values 
followed by Chi-square test to compare different categorical variables for women with and 
without HIP and IR at p < 0.05. Variables assessed included overweight and obesity using 
MUAC and BMI categories, family history of diabetes, edema, hypertension, gestational age, 
maternal age, proteinuria, etc. The outcomes, which were IR and HIP, were dichotomized 
into two categories which were either having the condition or not having the condition. 
Multiple logistics regression by binary logistic was used to find associations of different 
factors with HIP and then with IR separately. Univariate analysis was run for each factor 
association with HIP and IR separately. All factors with P < 0.05 were entered in the 
multivariate analysis using stepwise backward elimination (Harrell, 2015). Crude and 
adjusted odd ratios were obtained for each factor associated with HIP and/or IR at p < 0.05 
(Wynants et al., 2017). 
3.7.4 Knowledge on hyperglycemia in pregnancy   
Data about knowledge on HIP were analyzed using SPSS where frequencies and percentages 
were obtained to classify women as having poor, moderate, or high knowledge on HIP. 
Factors influencing knowledge were assessed using logistic regression where both univariate 
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and multivariate analyses were run. The confounders of knowledge, such as age, parity and 
income, were included in the multivariate analysis and significance was set at p < 0.05. 
3.7.5 Risk score data 
All women with DIP were excluded from the analysis to develop a tool based on GDM cases. 
Chi-square test was used for comparing the selected categorical variables and student t-test 
for the continuous variables between women with and without GDM. Blood glucose values 
were dichotomized as having GDM or not having the condition. Binary logistic regression 
was used and univariate analysis was done for each variables independent association with 
GDM where crude odd ratios were obtained (Wynants et al., 2017).  
All variables with p < 0.05 were entered in the multivariate analysis where adjusted odd 
ratios and regression of coefficients were obtained (Harrell, 2015). All variables with p < 0.1 
remained in the final model to avoid exclusion of important variables which potentially 
contributes to the development of GDM. The confidence intervals in each analysis were 
obtained and recorded. The final risk score model was developed based on the regression 
coefficients of each variable. The performance of the model was analyzed using AUC, 
specificity and sensitivity at a selected threshold which could give reasonable values.  Utility 
of the model was assessed using the Net Benefit (NB) which was obtained by different 
combination of true and false positive values. This was analyzed in R-statistic 3.61 by 
running the decision curve function.         
3.8  Ethical consideration 
The study was approved by the Tanzania National Institute for Medical Research (NIMR) 
and was given ethical clearance certificate with a reference number 
NIMR/HQ/R.8a/Vol.IX/2694 (Appendix 3). Participants signed an informed consent which 
clearly explained the aim, procedure, benefits and potential negative effects of the study 
(Appendix 2). Anonymity was ensured using numbers to represent the names of the women 
during data handling and confidentiality by having a specific room where research activities 






RESULTS AND DISCUSSION  
4.1  Results  
A total of 500 pregnant women were recruited whereby 94% (n = 468) consented to 
participate in the study. All 76 pregnant women with HIP were referred to the doctor for 
further actions and followed up by phones to understand their conditions and actions taken 
for more advices.   
4.1.1  Demographic characteristics of participants  
A total of 468 pregnant women participated in the study at Ngarenaro and Kaloleni Health 
Centers. The mean age of pregnant women was 28 years (SD ± 5.84), of which 65.6% were ≥ 
25 years old. Majority of the women were married (93.8%, n=459), and over half had 
attended primary school education (58.8%, n=275). About 56% (n=261) of the pregnant 
women were self-employed, primarily in small business earning an average income of < 250 
000 Tanzanian Shillings (TSH) per month (approximately < 110 United States Dollars) 
(Table 1). 
Table 1:  Demographic characteristics of participants (N=468)    
Respondent Variables               Frequency                  Percent     
Education levels    
    Informal education 8 1.7 
    Primary level 275 58.8 
    Secondary level 164 35.0 
    College/University 21 4.5 
Marital status    
    Single         16 3.4 
    Married or Cohabiting 439 93.8 
    Divorced/Separated  13 2.8 
Occupational status    
    Formally employed 46 9.8 
    Self employed 261 55.8 
    Unemployed 161 34.4 
Income per month (TSH)   
    <250 000 255 54.5 
    250 000-450 000 33 7.1 
    ≥500 000 13 2.8 
    Don’t know 167 35.7 
Age                       
   < 25 years 164 35.0 
    ≥ 25 years         304 65.0 
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The mean gestational age during the first ANC visit was 18 weeks (SD ± 5.62) and 28.5 
weeks (SD ± 3.82) at the commencement of this study. Nearly, 38% (n=177) of the pregnant 
women were ≥ 28 weeks of gestation at the time of entry to the study with 50.4% (n=236) 
reported as second or third gravidity (Table 2).  
Table 2: Demographic and selected maternal characteristics of the women (N=468)  
Respondent Variables  Frequency Percent Mean (±SD) 
Gestational age at first visit    
   <12 weeks 57 12.2  
   12-24 weeks 363 77.6 18 (SD ± 5.62) 
   25-36 weeks 48 10.2  
Gestational age at study commencement    
   24-28 weeks 291 62.2 28 (SD ± 3.82) 
   >28 weeks 177 37.8  
Gravidity     
    Prime  142 30.3  
    Second and third 236 50.4 3 (SD  ± 1.20) 
     Fourth and above  90 19.2  
4.1.2  Anthropometric measurements of pregnant women  
About half of the pregnant women were able to recall their pre-pregnancy weight. The mean 
of the self-reported pre-pregnancy weight was 67 kg (SD ± 12.5). This weight was used to 
determine pre-pregnancy BMI of the pregnant women. The measured mean height was 159 
cm (SD ± 6.3), body fat 33.7% (SD ± 7.2), and MUAC 27 cm (SD ± 3.8). About 10.3% 
(n=48) of the women were hypertensive and 20.3% (n=95) had edema (Table 3).  
Table 3: Anthropometry of the pregnant women (N=468 and N=238 for pre-pregnancy  
               weight) 
Variables tested  Frequency Percent Mean (SD) 
Body fat percentage    33.4 (SD ± 7.8) 
Self-reported  pre-pregnancy  
weight (kg) (n=238) 
  
67 (SD ± 12.5) 
Height (cm)   159 (SD ± 6.3) 
Hypertension     
    Yes 48 10.3  
    No 420 89.7  
Edema     
   Yes  95 20.3  
   No 373 79.7  
 
Pre-pregnancy BMI of the pregnant women was determined in which, 25.2% (n=60) were 
classified as overweight and 22.7% (n=54) obese. About 36% (n=164) of the women had 
MUAC ≥ 28 cm which is also an indicative of overweight or obesity (Fig. 11).  
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Figure 11: Nutrition status classified by body mass index (BMI) and mid upper arm                       
                   circumference (MUAC) measurements 
4.1.3  Prevalence of  hyperglycemia in pregnancy among pregnant women   
(i)  Laboratory glucose tests  
All pregnant women who participated in the study (100%, n=468) completed fasting blood 
glucose tests and 97.8% (n=446) underwent the OGTT procedure. Among the assessed 
pregnant women, 10.9% (n=51) reported to have one or more symptoms of diabetes such as 
extreme tiredness, diaphoresis (excessive sweating), and polydipsia (excessive thirst). Urine 
glucose test revealed that 0.9% (n=4) of the pregnant women had diabetes while 8.5% (n=40) 
had trace amount of glucose in the urine. Generally, HIP was prevalent in 16.2% (95% CI: 
13-19.9) of the participated pregnant women of which GDM was 13% (n=61) and DIP was 
3.2% (n=15) using the WHO (2013) criteria (Table 4).  
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Table 4: Laboratory tests for glucose and urine protein among pregnant women 
(N=468)   
Variables Tested  Frequency Percent 
Glucose testing   
    Completed fasting glucose tests  468 100.0 
    Completed OGTT 446 97.8 
Glucose status    
    Normal 392 83.8 
    HIP 76 16.2 
    DIP 15 3.2 
    GDM 61 13.0 
Having any symptoms of diabetes   
   Yes 51 10.9 
   No 417 89.1 
Glucose test in urine   
  Positive 4 0.9 
  Negative 424 90.6 
  Trace 40 8.5 
 (ii)  Mean glucose comparisons during pregnancy 
The overall mean for fasting blood glucose was 4.5 mmol/L (SD ± 1.3), with the HIP sub-
group having a mean of 6.4 mmol/L (SD ± 1.5), yielding a significantly higher (p<0.001) 
mean compared to the non-HIP group (4.2 mmol/L, SD ± 0.9). The overall mean for OGTT 
was 5.5 mmol/L (SD ± 1.06) and significantly higher (p<0.001) among the HIP (8.3 mmol/L, 
SD ± 1.3) compared to the non-HIP group (5.5 mmol/L, SD ± 0.1) (Table 5). 
 
Table 5: Mean blood glucose comparisons between women with and without                 
hyperglycemia in pregnancy (N=468) 
Variables Tested  Frequency Mean SD P-value 
Fasting blood glucose      
   General fasting blood glucose 468 4.5 ±1.3  
   Normal (< 5.1 mmol/L) 397 4.2 ±0.9 <0.001* 
   HIP (≥ 5.1 mmol/L) 71 6.4 ±1.5  
OGTT      
   General OGTT values  446 5.6 ±1.06  
   Normal (< 8.5 mmol/L) 436 5.5 ±0.1 <0.001* 
   Glucose intolerance (≥ 8.5 mmol/L) 10 8.3 ±1.3  




(iii)  Comparisons of the selected characteristics between women with and without 
hyperglycemia in pregnancy  
Chi-square analysis was run to identify categorical variables which are associated with HIP 
(Table 6). 
Table 6: Comparison of selected characteristics between women with and without   
               hyperglycemia in pregnancy       
Variable  With HIP Without HIP P-value 
MUAC    
   < 28cm (Normal) 37(12.4%) 262(87.7%) 0.003* 
    ≥ 28cm (overweight/obese 39(23.1%) 130(76.9%)  
BMI pre-pregnancy    
    Underweight  or Normal 19 (15.3%) 105(84.7%) 0.251 
    Overweight or Obese 24 (21.1%) 90(78.9%)  
Family history of diabetes     
    Yes 35(44.9%) 43(55.1%) <0.001* 
    No 41(10.5%) 349(89.5%)  
Previous delivery to ≥ 4kg baby    
   Yes 48(47.1%) 54(52.9%) <0.001* 
   No 10(4.4%) 219(95.6%)  
Maternal age     
   <25 years  24(14.4%) 143(85.6%) 0.414 
    ≥ 25 years  52(17.3%) 249(82.7%)  
Symptoms of T2DM    
   Yes 25 (49.0%) 26 (51.0%)  
   No 51(12.2%) 366(87.8%) <0.001* 
Previous stillbirth (>20weeks of gestation)     
   Yes 10 (15.9%) 53(784.1%) 0.467 
   No  48(17.9%) 220(82.1%)  
Previous neonatal death(within 28 days of life)    
   Yes 1 (10.0%) 9 (90.0%) 0.538 
   No 29(20.1%) 115(79.9%)  
Hypertension     
    Yes  14(29.2%) 34(70.8%) 0.550 
    No 62(14.8%) 358(85.2%)  
Insulin resistance     
   Yes  19(38.8%) 30(61.2%) <0.001* 
   No 25(13.7%) 158(86.3%)  
Protein in urine    
   Yes 1(25.0%) 3(75.0%) 0.254 
   No  65(15.3%) 359 (84.7%)  
   Trace 10(25.0%) 392(75.0%)  
Gestational age     
  24-28 weeks 49(16.8%) 242(83.2%) 0.554 
   >28 weeks 27(15.3%) 150(84.7%)  
*Significant at p < 0.05 
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The results shown that, HIP was significantly higher (p < 0.000) among women with family 
history of T2DM (44.9% vs 10.5%, p < 0.001); MUAC ≥ 28 cm (23.1% vs 12.4%, p = 
0.003); history of previous macrosomic delivery (47.1% vs 4.4%, p < 0.001); symptoms of 
T2DM (49.1% vs 12.2%, p < 0.001), and IR (38.8% vs 13.7%, P < 0.001) (Table 6). 
The observed prevalence of HIP did not differ significantly among pregnant women with, 
history of previous stillbirth, high gestational age (> 28 weeks), neonatal death and delivery 
through caesarean section, hypertension, advanced maternal age, protein in urine 
(proteinuria), smoking and alcohol intake habits (p > 0.05) (Table 6). 
(iii)  Factors associated with hyperglycemia in pregnancy  
Selected risk factors were analyzed using multiple logistic regression analysis to determine 
their association with HIP. A significant association was observed in women with high body 
fat percentage (AOR 1.3, 95% CI: 1.3-1.4), family history of T2DM with (AOR 7.0, 95% CI: 
3.1-15.6) and history of delivery macrosomic babies ≥ 4 kg at birth (AOR 2.0, 95% CI: 1.4-
5.3) in the first model (Table 7).  
The second model replaced body fat percentage with MUAC and the association remained 
consistently significant in all factors of the first model with the addition of MUAC (AOR 1.2, 
95% CI: 1.1-1.3) (Table 7).  
The width of interval gives an indication for precision of the point estimate. Hence, the wide 
ranges in CIs observed for family history of T2DM and fetal macrosomia may be due to the 
random distribution effects, meaning that the sample population was not sufficient to give 
inferences. However, the information is useful and can act as a starting point for additional 










Table 7: Odd ratios of select risk factors for hyperglycemia in pregnancy  
Risk factors Crude OR(95%CI) P-value 
Body fat percentage  1.3(1.2-1.4) <0.001* 
MUAC 1.2(1.2-1.3) <0.001* 
BMI 1.0(1.0-1.1) 0.294 
Family history of 
T2DM  
  
   No 1  
   Yes  6.9(4.0-12.0) <0.001* 
Previous delivery ≥ 4 
kg baby 
  
   No 1  
   Yes  5.9(3.1-11.0) <0.001* 
Delivery( < 37 weeks 
of gestation) 
  
   No 1  
   Yes 1.2(0.4-3.8) 0.779 
Birth modality   
   Normal delivery 1  
   Caesarian section 1.1(0.6-1.7) 0.858 
             Model 1         Model 2  








Body fat percentage  1.3( CI:1.2-1.4) <0.001 NA  
MUAC NA  1.2 (CI: 1.2-1.3) <0.001* 
Family history of 
T2DM 
    
   No 1  1  
   Yes  6.9(CI: 3.1-15.6) <0.001 6.0(CI: 3.0-12.0) <0.001* 
Previous delivery to       
≥ 4kg babies 
    
   No 1  1  
   Yes  2.3(CI: 1.0-5.3) 0.049 3.5(CI: 1.7-7.4) 0.001* 
Association of HIP and the presence of one or more symptoms for T2DM 
Symptoms of T2DM     
   No 1  1  
   Yes 2.8(CI: 1.5-6.9) 0.023 3.7(CI: 2.6-4.2) 0.002* 
Note: Univariate analysis also included history of neonatal death, blood pressure smoking 
habit, gravidity /parity and alcohol intake, maternal and gestational age, with no significant 
association with HIP. In multivariate analysis, body fat was replaced by MUAC in model 
2.The abbreviation NA means not applicable in the particular model. *Significant at p<0.05  
4.1.4  Insulin resistance among pregnant women 
The prevalence of IR was observed to be 21.3% (n=49) and 9.6% had high levels (≥ + 2) of 
protein in the urine (proteinuria) among 230 pregnant women who were assessed. The overall 
mean of IR level was 2.2 ± 1.74 of which IR cases had a significantly (p < 0.001) high mean 
of 4.4 (±2.15) compared to the normal women with a mean of 1.4(±1.15) (Table 8). 
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Table 8: Laboratory tests for proteinuria and insulin resistance among pregnant women   
               (N=230)   
Variables Tested  Frequency Percent Mean (SD) 
Insulin resistance status    
    Insulin level 230 100.0 2.2 (± 1.74) 
    Normal 181 78.7 1.4(±1.15) 
    IR cases   49 21.2 4.4(±2.15) 
 Protein in urine    
   Positive 22 9.6  
   Negative  145 63.0  
   Trace 63 27.4  
 (i)  Factors associated with insulin resistance in pregnancy 
Multiple logistic regression analysis was performed to determine the associations among 
selected risk factors with IR. Insulin resistance was significantly associated with high body 
fat percentage (AOR 1.7, 95%CI: 1.5-2.0), family history of T2DM with (AOR 2.8, 95% CI: 
1.2-6.3), protein in urine (proteinuria) (AOR 3.4, 95% CI: 1.1-10.7), presence of edema 
(AOR 3.0, 95% CI: 1.3-6.7), and hypertension (AOR 2.5, 95% CI: 1.1-5.6) (Table 9).  
Maternal age, MUAC, pre-gestational BMI, previous delivery of baby ≥ 4 kg were not 
associated with IR after adjusting for other risk factors (p > 0.05). Moreover, IR was 
significantly associated with HIP (p < 0.001) (Table 9). 
The wide CI indicates that a large range of possible values must be included in order to be 
95% confident that the parameter lies within the CI. Hence, CIs for family history of T2DM 
and the presence of protein in urine suggests that the sample population is not large enough to 
make inferences, but recognizes that this insight is practically useful and indicates the need 









Table 9: Association of select factors with insulin resistance  
Risk factors Crude OR (95%CI)    P-value Adjusted OR (95% CI) P-value 
Body fat percentage  1.8(1.4-2.1) 0.001* 1.7(1.5-2.0) 0.023* 
Age of  woman 1.1(1.0-1.1) 0.079 NA  
MUAC 1.1(1.0-1.2) 0.362 NA  
Hypertension     
   No 1  1  
   Yes 2.9(1.6-4.9) 0.001* 2.5(1.9-4.6) 0.025* 
Family history of T2DM      
   No 1    
   Yes  2.2(1.1-4.6) 0.031* 2.8(1.2-6.3) 0.016* 
Previous ≥ 4 kg babies     
   No 1  1  
   Yes  2.4(1.0-5.6) 0.049* 1.2(1-1.2) 0.045* 
BMI      
   < 25 kg/m2 1    
   ≥ 25 kg/m2 0.5(0.2-1.5) 0.100 NA 0.100 
Protein in urine     
   Negative  1  1  
   Positive  3.5(1.3-9.8) 0.017* 3.4(1.1-10.7) 0.033* 
Edema      
   No 1    
  Yes 3.5(1.7-7.4) 0.001* 3.0(1.3-6.7) 0.010* 
Relationship between IR and HIP 
IR as risk factor for HIP 3.8(1.9-7.7) 0.001*    NA  
Note: The univariate analysis also included gestational age, preterm delivery (<37 weeks of 
gestation) as well as stillbirth and neonatal death with no significant association with IR. The 
abbreviation AOR means Adjusted Odd Ratio, CI - Confidence Interval, NA means Not 
Applicable for multivariate analysis and IR –Insulin Resistance.  *Significance  at p < 0.05 
4.1.5  Knowledge on hyperglycemia in pregnancy among pregnant women   
(i)  Knowledge about hyperglycemia in pregnancy  
Among the interviewed women, very few knew about the existence of HIP (10.7%, n=50) 
and 36% (n=18) correctly defined HIP as diabetes with first recognition during pregnancy. 
Few participants were able to mention the effects of HIP (23%, n=14), such as stillbirth, 
neonatal death, delivery of a microsomal infant (≥ 4 kg) at birth, and development of diabetes 
mellitus later in life for the mother and the newborn. Moreover, few women (26%, n=13) 
knew some symptoms for HIP, such as extreme tiredness, diaphoresis (excessive sweating), 
and polydipsia (excessive thirst).  In addition, 30% (n=15) of the women knew the causes/risk 
factors for HIP, and mentioned family history of T2DM and history of delivery big babies to 
be predictors for HIP (Table 10). 
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Table 10: Participants’ knowledge about hyperglycemia in pregnancy (N=468) 
 
(ii)  Factors influencing awareness about hyperglycemia in pregnancy among women 
Knowledge about HIP was significantly associated with education level (AOR 13.7, 95% CI: 
4.07-46.15) for secondary and (AOR 5.5, 95% CI: 1.78-16.76) for college/university levels. 
After adjusting for income, occupation, age and gravidity, knowledge remained significantly 
associated with education levels. The wide CI in the level of education means that the factor 
occurs in a small proportion of women who may not be the representative, thereby creating 
uncertainties as to whether the estimate of the parameter is precise (Table 11). However, it 
important to note that the obtained information is still valuable and calls for additional studies 
such as longitudinal or population-based approaches.  
Variables tested  Frequency Percent 
Knowledge on the existence of HIP   
   Yes  50 10.7 
    No 418 89.3 
Know the meaning of HIP   
   Yes 18 36.0 
    No 32 64.0 
If yes what is HIP   
     Diabetes first occurring in pregnancy 18 36.0 
     Do not know the meaning 32 96.2 
Know the symptoms of  HIP   
     Yes 13 26.0 
     No 37 74.0 
If yes what are the symptoms of HIP   
    Frequent urination  6 46.0 
    Tiredness 3 23.0 
    Frequent thirsty 4 31.0 
Know the effects of  HIP   
     Yes 14 23.0 
      No 36 77.0 
If yes what are the effects of HIP   
      Overweight baby 2 14.2 
      Diabetes later in life to mother and child 6 42.9 
      Prenatal death 6 42.9 
Understand the risk (causes) of HIP   
     Yes 15 30.0 
     No 35 70.0 
If yes what are the causes of HIP   
     Family history of T2DM  12 80.0 
     Previous delivery to > 4kg babies  3 20.0 
Reported sources of information about HIP   
     During ANC 12 24.0 
     Different media (Internet, TV, what-sap etc.) 38 76.0 
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Table 11: Participants’ attributes associated with awareness of hyperglycemia in              
                 pregnancy  
Risk factors    n Crude OR(95%CI)     P-value Adjusted  OR(95%CI)    P-value 
Education levels      
    Primary /informal 283                    1                          1  
    Secondary 164 25.5(10.4-62.5) <0.001* 13.7(4.1-46.2) <0.001* 
    College/university 21 12.6(5.2-30.6) <0.001* 5.5(1.8-16.8)   0.003* 
Gravidity      
    Prime  142         1            1  
    Second and third 236 1.46(0.67-3.21) 0.341 1.2(0.2-2.5) 0.567 
     Fourth and above  90 2.37(0.92-6.16) 0.050 2.1(0.5-4.7)   0.076 
Maternal age      
< 25years  164         1                1  
≥ 25years  304 1.3(0..4-2.4) 0.088 1.1(0.6-1.8) 0.956 
Employment status      
    Unemployed 161           1               1  
   Non-formal    
    employed 
261     0.1(0.1-0.3)  0.824 0.14(0.1-0.4) 0.638 
    Formally employed 46 1.1(0.5-2.3) <0.001* 1.0 (0.3-2.5) 0.631 
Income level (Tshs)      
    <250 000 255             1                1  
     250 000-450 000 33 7.1(1.6-31.7) 0.011* 2.1(1-47.0) 0.638 
     >450,000 13 4.7(1.4-21.3) 0.045* 0.6(0.1-12.0) 0.680 
     Not sure 167 0.1(0.1-0.3) 0.905 0.1(0.0-0.5)  
Note: Large Confidence Intervals (CI) may be due to a small number of women falling in the 
category. Abbreviation: OR–Odd ratio. *Significant at p < 0.05 
(iii)  Practices reported by women on hyperglycemia in pregnancy screening and  
           management  
During the assessments for practices in screening, and managements of HIP, about 8.1% (n= 
38) of the pregnant women reported to have been screened for diabetes in their previous 
pregnancies using urine samples with five (13.2%, n=5) reporting positive results in their 
previous pregnancy. The few women who were diagnosed with diabetes were provided with 
counseling and referred to the doctor/regional hospital for further actions but no follow-up 









Table 12: Women’s reported practices on hyperglycemia in pregnancy screening and  
                  management (N=468) 
Variables Tested  Frequency Percent 
Tested glucose  in previous pregnancies   
    Yes 38 8.1 
    No 266 56.8 
    Not sure  164 35.1 
Testing method used    
    Urine 38 100.0 
    Blood 0     0.0 
If tested what was the status   
    Normal 33 86.8 
    High/detected 5 13.2 
If high were you treated    
   Yes 3 60.0 
   No 2 40.0 
If yes, how were  you treated   
   Counseled and refereed to hospital 3 100.0 
    Medication 0     0.0 
Followed up after diagnosis     
    Yes 0     0.0 
    No 5 100.0 
4.1.6  Development of the risk scores 
The risk score for identification of women with or at risk of GDM was developed using 
logistic regression analysis (binary logistic) with stepwise backward selection procedure. 
Before analysis was done, all women with DIP were excluded from the analysis as the aim 
was to develop a tool for identification of women at risk of GDM which is the highly 
increasing type of HIP. 
(i) Odd ratios and regression coefficients from univariate analysis  
From the univariate logistic regression model, potential predictors for the development of 
GDM among pregnant women included; increased MUAC, body fat percentage, history of 
stillbirth in previous pregnancy, family history of T2DM and delivery model (Caesarean 
section) which may indicates a history of big babies in previous pregnancies. In addition to 
history of delivery macrosomic babies which may indicate that women had high level of 
glucose in her previous pregnancy which was transferred to the fetus, and IR at P < 0.05. On 
the other hand, hypertension during pregnancy and before pregnancy and after delivery, 
edema, smoking habits, alcohol intake, preterm delivery, gravidity, maternal age ≥ 25 years 
and proteinuria were not significantly associated with HIP at p > 0.05 (Table13). Insulin 
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resistance was not included in the final model due to costs associated with laboratory 
analysis. 
Table 13: Univariate analysis of risk factors associated with gestational diabetes                    
                 mellitus          
Variables  B Crude 
OR 
CI P-value 
Mothers age ≥ 25yrs 0.10 1.01 0.96-1.05 0.846 
Macrosomic (≥ 4kg) 1.09 2.99 1.63-5.48 <0.001* 
T2DM history 1.66 5.27 2.88-9.63 <0.001* 
MUAC 0.47 1.60 1.44-1.77 <0.001* 
Body fat  0.49 1.65 1.46-1.86 <0.001* 
Parity 0.09 1.10 0.46-2.64 0.835 
Preterm delivery(< 37weeks) 0.13 1.14 0.32-4.02 0.837 
Stillbirth 1.33 3.78 1.34-10.63 0.012* 
Neonatal death -19.44 0.00 0.00-0.01 0.999 
Blood pressure in pregnancy 0.32 1.38 0.73-2.60 0.327 
Blood pressure before pregnancy -19.36 0.00 0.00-0.01 0.999 
Alcohol intake  0.09 1.10 0.18-6.57 0.917 
Smoking habits -19.35 0.00 0.00-0.08 0.999 
Presence of edema -0.01 0.99 0.50-1.96 0.967 
Proteinuria  0.25 1.28 0.34-4.84 0.715 
Presence of glucose in urine 1.03 1.11 0.10-12.04 0.931 
IR 1.77 6.76 5.67-8.22 <0.001* 
Note: The word “No” was used as reference in categorical variables. Univariate also included 
stillbirth and neonatal death in the current pregnancy which had no significant association 
withn GDM *Significant at p< 0.05 
(ii) Adjusted odd ratios, regression coefficients and scores from multivariate analysis  
From multivariate model, factors found to be predictors of GDM were MUAC ≥ 28 cm (AOR 
1.28 95% CI 1.08-1.56), body fat percentage (AOR 1.77, 95% CI 1.37-2.294), family history 
of type 2 diabetes (AOR 8.34, 95% CI 1.91-36.43), and previous history of delivery 
macrosomic babies (AOR 7.99, 95% CI 1.95-32.79) (Table 14).  
Then a cut off point for body fat percentage was developed using the ROC and found that the 
risk for GDM is increasing with the body fat of ≥ 38%. Backward elimination method 
removed hypertension, preterm delivery, stillbirth and maternal age which were not 
significantly associated with GDM (p > 0.1). The significant variables were used to develop a 
risk score model to identify women with and /or at risk of GDM (Table 14). The risk for 
GDM increased among woman with 2 to 49 scores (Table 14). 
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Table 14: Multivariate analysis and risk scores  
Variables  B OR CI P-value B x 10 
Macrosomic 2.00 7.99 1.95-32.79 0.004* 20 
T2DM history 2.12 8.34 1.91-36.43 0.005* 21 
MUAC 0.24 1.28 1.080-1.58 0.019* 2 
Body fat 0.57 1.77 1.37-2.29 <0.001* 6 
Total points      49 
R2  of  0.80 and  ROC  
0.97 
NA NA 0.95-0.99 <0.001* NA 
Different threshold values for the risk of HIP 
Threshold value  Sensitivity Specificity PPV NPV  
0.2 0.98 0.46 0.68 0.97  
4 0.96 0.23 0.57 0.89  
7 0.93 0.13 0.54 0.75  
10 0.91 0.11 0.53 0.65  
Note: Significant p≤ 0.1. The abbreviation OR means odd ratio, CI confidence interval, NA-
not applicable , PPV-Positive predictive value, NPV- Negative predictive value 
Among the risk factors involved in the model, family history of T2DM contributes much on 
the development of GDM followed by tendency of delivery macrosomic babies, high body fat 
percentage and lastly increased MUAC (Fig. 12).  
Figure 12: Contributions of each risk factor in the model  
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(iii) Performance of the developed model 
The threshold of 0.2 was selected as cut off for the performance of the model to reduce the 
number of false negatives and identify most of the women at risk of the condition. The model 
was found to perform well in the studied ANC setting with an AUC of 0.97 (95% CI 0.96-
0.99, p < 0.001) (Fig. 13), sensitivity of 0.98, specificity of 0.46 as well as PPV of 0.68 and 
NPV of 0.97 at a selected cut off of 0.2. Moreover, the regression has the pseudo-R squared = 
80.03% which implies that the model is a good predictor of GDM (Table 14). 
 
 
Figure 13: Receiver–operating characteristics curve (ROC) for performance of the risk  





(iv)  Comparison of performance of the risk score and other models   
The performance of the risk score model was significantly higher with AUC of 0.97 (95%CI 
0.95-0.99, p < 0.001) compared to that of fasting glucose test with AUC of 0.96 (95%CI 
0.92-0.99, p < 0.001), and OGTT with AUC of 0.64 (95% CI 0.56-0.72, p = 0.002). Urine 
glucose test model performed poorly with an AUC of 0.54 (95% CI 0.45-0.63, p = 0.38 as it 
could not discriminate women with GDM and those without the condition (Fig. 14). 
 
Figure 14: Receiver–operating characteristics curve for performance of the risk score, 





(v) Clinical utility of the model 
Clinical utility of the model was assessed using the Net benefit (NB) curve which shows that, 
in different combinations of true and false positive values, there is high benefit of screening 
for GDM using the risk score model at any chosen threshold. For-example the NB of using 
risk scores is 83%, while universal screening for all women is 80% at the threshold of 0.2. 
When the threshold was chosen at 0.6, the NB of GDM screening using the risk score model 
was still high (80%) compared to universal screening for all women which was 62% (Fig. 
15). This implies that, when risk score is used more pregnant women with high risk of GDM 
benefit from the screening program.  
 




(vi) The risk factors checklist 
The predictors used to develop risk score in addition to the risk factors for IR were simplified 
into a simple checklist which involved macrosomic babies as a result of high maternal 
glucose levels during pregnancy, high MUAC ≥ 28 cm and body fat ≥ 38%, family history of 
T2DM as well as edema, and hypertension which are risk factors for IR (Table 15). In this 
case, having one or more of the risk factors indicated in the checklist, exposes a woman to the 
risk of developing GDM which indicates the need for further testing to confirm.  
Table 15: The risk factors checklist 
 Risk factors for GDM 
1 Tendency of delivery macrosomic babies (≥ 4 kg) 
2 Family history of T2DM  
3 High MUAC ≥ 28 cm 
4 High body fat ≥ 38%  
5 Edema and/or hypertension 
Note: The occurrence of preeclampsia manifested by edema and hypertension is a risk factor 
for IR which is associated with early GDM 
4.2  Discussion  
4.2.1  Overview  
The current study was conducted among pregnant women in Arusha District to establish the 
prevalence of HIP and develop a simplified method for identification of women with /or at 
risk of GDM in Tanzania’s ANC settings with limited recourses. This will enhance self-care 
and evidence-based treatment for appropriate and efficient use of the limited resources. The 
study also established the prevalence of IR, and knowledge about HIP among pregnant 
women in the selected ANC centers.  
4.2.2  Prevalence of hyperglycemia in pregnancy and associated risk factors among  
             pregnant women  
The overall prevalence of HIP was 16.2%, of which 3.2% had DIP and 13% GDM according 
to WHO (2013) criteria. The observed prevalence of HIP may increase burden to the health 
system if no immediate actions are taken. The need exists to explore the associated 
modifiable risk factors including body fat percentage to enhance self-care practices and 
prevent poor pregnancy outcomes as well as T2DM later in life. A similar study conducted in 
Kilimanjaro Region, Tanzania using the same WHO (2013) criteria reported that the 
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prevalence of DIP was 3% and  19.5% had GDM (Njete et al., 2018) which is higher than the 
current study. The differences observed may be due to nature of the diets, cultural differences 
in food preparation, and care during pregnancy, as well as after delivery which need further 
explorations.  A similar study in Nigeria reported that the prevalence of GDM was 15.7% and 
DIP was 4.8% according to WHO (2013) criteria (Imoh et al., 2017). In India likewise, HIP 
was prevalent in 18.9% of the studied population where by 16.3% had GDM and 2.6% had 
DIP (Nielsen et al., 2016) using the same WHO (2013) criteria.  In these studies, the 
prevalence of GDM is higher than DIP. As long as GDM disappears after delivery if 
managed, early interventions could help to prevent poor pregnancy outcomes and its 
progression to T2DM later in life.  
The prevalence of HIP in the present study was significantly associated with high body fat 
percentage, family history of T2DM, MUAC ≥ 28 cm and previous delivery of ≥ 4 kg babies 
at birth. Increased body fat percentage and MUAC are indicatives of overweight and obesity 
which are positively associated with development of HIP. Excess body fat and a high 
proportion of large adipocytes may significantly contribute to IR later in pregnancy. Adipose 
tissue produces numerous factors (adipocytokines), most of which act as hormones. For 
example adiponectin is the main adipose-specific protein which may have a role in the 
pathogenesis of obesity. As obesity is a predisposing factor for development of diabetes 
mellitus in general and GDM in specific, this might explain the indirect involvement of a 
decreased adiponectin in the pathogenesis of diabetes mellitus. Moreover, obesity is linked to 
increased circulating levels of leptin and the inflammatory markers of TNF-α and C-reactive 
protein  as well as decreased levels of adiponectin, which are associated with IR and risk of 
GDM (Kautzky-Willer et al., 2001; Retnakaran et al., 2003; Retnakaran et al., 2004; 
Williams et al., 2004). 
On the other hand, BMI obtained from the recalled pre-pregnancy weight was not 
significantly associated with HIP even after been replaced for MUAC and/or body fat 
percentage in the models, making it a weak determinant of HIP. A major limitation with 
recalled weight before pregnancy is that, women may over or under-estimated their pre-
pregnancy weight which may cause bias. In this case, body fat percentage together with 
MUAC can be used instead of BMI as determinants of HIP due to their independent 
association with HIP which helped to reduces biases of recalled weight.  
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In the current study, almost half of the pregnant women could not recall their pre-pregnancy 
body weight making it difficult to estimate pre-pregnancy BMI and pregnancy weight gain. 
This may be due to fact that majority of Tanzanians, including women, do not have tendency 
of assessing their nutritional status regularly unless in the case of the diseases and/or advised 
by the doctor. This finding is supported by Mwanri et al. (2014) who reported that BMI could 
not be estimated for most of the women, due to failure to recall their pre-pregnancy weight. 
Another similar study reported that, less than half of the pregnant mothers had an ability to 
recall their pre-gestational weight (Saldana et al., 2004).  
Although weight during pregnancy can be estimated with a recorded weight within fifteen 
weeks of pregnancy (Saldana et al., 2004), women in the current study started first ANC visit 
at a mean gestational age of 18 weeks making their pregnancy weights to be indeterminate. A 
similar study reported that, since most of the women appeared late to the ANC with a mean 
gestational age of 20 weeks, it was difficult to obtain their pre-gestational weight (Gale et al., 
2007). Hence, information on changes in body fat content is required due to its independent 
association with HIP and easy of estimations during pregnancy. This is further supported in a 
previous study which report that the risk of GDM was independently associated with high 
body fat percentage, similar to the findings in people with T2DM (Iqbal et al., 2007). 
Similarly, a study conducted in China reported that the percentage body fat was the strongest 
risk factor for GDM after adjusting pre-pregnancy BMI (Wang & Luo, 2019). With these 
associations, it is important to utilize these simple factors to identify pregnant women at risk 
for HIP so that prevention measures, such as lifestyle modifications, can be implemented to 
prevent poor pregnancy outcomes (Forsbach-Sanchez et al., 2005).   
Women with a history of delivery macrosomic babies (≥ 4 kg) at birth were at twice the risk 
of HIP compared to their counterparts even after adjusting for body fat percentage, pre-
pregnancy BMI, gestational age and MUAC. This may be attributed by a high maternal 
glucose level which was transferred to the fetus. This finding reveals how maternal health 
status is the determinant of health of the newborn. This occurs due to fetal hyperinsulinemia, 
which results from maternal fetal transfer of glucose (Xiong et al., 2001). It can also be due 
to elevation in plasma concentrations of placental hormones like progesterone, human 
chorionic somatomamotrophin and cortisol, which are designed to provide energy and 
nutrients for the developing fetus by providing more glucose, resulting in dysregulation of 
glucose metabolism (Asare-Anane et al., 2013; Fetita et al., 2006). Another study in South 
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Africa found that a previous history of delivery a baby weighing ≥ 4 kg at birth was an 
independent predictor of developing GDM (Adam & Rheeder, 2017). This finding means that 
a woman whose pregnancy resulted to a child with high birth weight, is at an increased risk of 
GDM in progressive pregnancies (Ross, 2006).  
In this study, women with family history of diabetes were almost seven times at greater risk 
of HIP compared to their non-affected counterparts meaning that HIP can be influenced by 
genetic predisposition and/or lifestyle practices, such as dietary intake and low physical 
activities. Another study showed that, GDM is considered to result from interaction between 
genetic and environmental risk factors (Shaat & Groop, 2007). Pregnancy triggers a series of 
metabolic imbalances that lead to a diabetic state in women who are already genetically 
predisposed to develop diabetes (Reece et al., 2009).  Of note, GDM and T2DM share a 
similar genetic background (Kwak et al., 2012), which might be a reason to why women with 
strong first-degree family history of T2DM are at high risk of GDM. Hence, genetic 
predispositions to T2DM or GDM should not be ignored. Other studies concur with the 
current finding that family history of diabetes remained significantly associated with GDM 
even after adjustment for other co-variates (Whelton et al., 2017; Leng et al., 2015).   
Some women with HIP reported having one or more symptoms of T2DM, such as extreme 
tiredness, diaphoresis, polydipsia and increased frequent urination. These symptoms were 
found to have a strong independent association with HIP even after adjusted for MUAC, 
BMI, gestational age and family history of T2DM. Considering the asymptomatic nature of 
GDM (ADA, 2010), these women may have pre-existing T2DM which was not diagnosed 
before pregnancy because, 3.2% (n=15) of the women had high glucose cut off points which 
indicated the presence of DIP. This may be attributed by a high prevalence of T2DM without 
access to screening services before pregnant hence, increasing their risk for pre-existing 
undiagnosed diabetes in pregnancy.  
Therefore, there is a need to promote pre-pregnancy preparations that include regular 
screening for diabetes for earlier efforts to be taken to prevent the development of HIP. 
Hyperglycemia in pregnancy has few or no symptoms and should be diagnosed by screening 
during pregnancy (Al-Noaemi & Shalaye, 2011). Another study reported that overt symptoms 
of GDM/HIP are rare and may be difficult to distinguish from normal pregnancy symptoms 
creating a need for confirmatory OGTT (ADA, 2010). Hyperglycemia in pregnancy can be 
influenced by first generation family history of T2DM and, when undiagnosed and 
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unmanaged, can lead into recurrent GDM in subsequent pregnancies and/or T2DM later in 
life (IDF, 2013; Leng et al., 2015). Hence, symptom clusters with risk factors can be used for 
identification of women who need screening for HIP especially in low income countries 
where universal screening is not possible due to resource constraints.   
4.2.3  Prevalence of insulin resistance and its determinants among pregnant women  
The prevalence of IR was present in 21.3% (n = 49) of the 230 studied women with 
significantly higher incidence among women with HIP compared to non-HIP. This finding 
may reflect that IR is a normal condition in pregnancy but may become dominant leading to 
HIP, especially among women with increased risk for diabetes.  Another similar study 
reported that women with GDM are more likely to experience IR than their non-GDM 
counterparts (Elkind-hirsch et al., 2010). Furthermore, increased serum insulin level at 
screening in early pregnancy can predict GDM because, the higher the serum insulin level, 
the earlier the manifestation of GDM (Bitó et al., 2005). 
Insulin resistance was significantly associated with high body fat percentage meaning that 
increased fat deposition exposes pregnant woman to IR condition; however, MUAC and pre-
pregnancy BMI were not associated with IR after adjusting for other risk factors. This 
divergence may reflect that pre-pregnancy BMI was determined for few pregnant women as 
the majority could not recall their pre-pregnancy body weight and determination of weight at 
early stage of pregnancy was not possible due to late start of ANC attendance. Another 
reason could be that the recalled weights are sometimes under-reported (i.e., most 
obese/overweight women report low weights) (Saleem et al., 2013).   
Pregnancy is associated with increased maternal adiposity and storage of carbohydrates and 
fat, as an evolutionary adaptation to facilitate successful lactation; but, the deposition within 
skeletal muscle and liver cells is a major contributory factor to IR (Ravikumar et al., 2005). 
Several studies have supported this finding, such as a study from Japan which reported a 
significant relationship between HOMA-IR and body fat percentage in patients with a normal 
or below normal BMI level (Sasaki et al., 2016). Similarly, a study from Turkey reported that 
body weight and BMI did not reflect body composition, particularly body fat, which is 
considered to be closely related to IR (Gur et al., 2014). Svensson et al. (2016) in Sweden 
reported that body fat mass and the proportion of very large adipocytes were strongly 
associated with gestational IR.  
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Women with a family history of T2DM experienced three times the risk of IR than their 
counterparts. This finding may reflect that GDM and T2DM share a similar genetic 
background, which may clarify why women with strong first-degree family history of T2DM 
are at high risk of GDM (Kwak et al., 2012). Another similar study found family history of 
diabetes and hypertension to play important roles in IR syndrome (Velasquez-Mieyer et al., 
2005). 
Maternal age was not significantly associated with IR after adjusting for body fat percentage, 
family history of T2DM, hypertension, presence of edema, and proteinuria. This is because, 
IR was also prevalent among younger women where 13 out of 49 women with IR were below 
25 years of age. This finding could be explained by overweight and obesity, which often 
increases with age however, more recent trends have shown that women become obese and 
overweight at a younger age as in this study where 10 out of 47 obese/overweight women 
were below 25 years of age. Another similar study reported that the prevalence of 
overweight/obesity among young adults (18 to 25 years old) in developing countries is 
increasing mostly among females (Poobalan & Aucott, 2016).  
This increases their chance for developing NCDs at younger age, such as diabetes mellitus 
and cardiovascular diseases. Another study reported no significant difference in age of the 
mothers in IR case groups (Sonagra et al., 2014). Contrary to the current study’s finding, 
Karakelides et al. (2010) reported that age affects insulin sensitivity, meaning that increase in 
age, leads to progressive increase in IR which is a proxy for GDM and T2DM. Moreover, age 
of onset of diabetes and pre-diabetes is declining while age of childbearing is increasing. 
Overweight and obesity is increasing among women of reproductive age according to 
Tanzania National Nutrition Survey (MoHCDGEC et al., 2018) making more women to enter 
pregnancy with some risk factors that make them vulnerable to IR and GDM (Hod et al., 
2015).  
Pregnant women with hypertension had almost three times increased risk for IR than those 
with normal blood pressure levels. Most of the pregnant women with IR were also found to 
have HIP, which is associated with development of pregnancy hypertension. A similar study 
concurs with these findings that diseases, such as hypertension and diabetes, are associated 
with existence of IR (Catalano, 2010). Hyperinsulinemia may predispose a woman to 
hypertension by increasing renal sodium reabsorption and stimulation of the sympathetic 
nervous system (Reaven, 1995). Furthermore, the features of the IR syndrome may persist 
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many years after pregnancy raising the possibility of increased risk for future cardiovascular 
disease which is manifested by hypertension. Thus, interventions to reduce IR may reduce 
risk of both hypertension during pregnancy and later life cardiovascular complications (Seely 
& Solomon, 2003).  
Likewise, pregnant women with edema which is normal condition but was also observed in 
the arms and faces with an addition of proteinuria, experienced three times the risk of IR as 
compared to their counterparts even after adjusted for body fat percentage, family history of 
T2DM, hypertension and age. As the presence of edema, proteinuria and/or hypertension 
indicate the risk for preeclampsia, women with risk for preeclampsia may also experience IR.  
A study from Iran found that IR is considered a risk factor for preeclampsia pathogenesis 
meaning that preeclampsia is associated with increased IR before the onset of the disease 
(Abhari, 2014). In addition, research done at Kermanshah in Iran reported that women who  
developed  preeclampsia  had  higher  fasting  insulin  levels  at  the  second trimester,  before  
the appearance of clinical  signs of preeclampsia, as well as fasting insulin level progressively 
increases when disease develops (Malek-Khosravi & Kaboudi, 2004). These findings show 
that preeclampsia and IR have a casual and effect relationship.  
Hence, identification of women with IR and exploration of associated risk factors can be a 
starting point towards the prevention of GDM as well as T2DM later in life.  Although IR has 
been found to be significantly associated with several risk factors, the CI of some variables 
were wide which may be due to a relatively small sample of 230 pregnant women. This may 
affect results as it implies that there is not enough information to confidently conclude that 
the observed outcome is within the population parameters, although the results are still 
practically meaningful. Hence, additional research with a larger sample is needed (Sim & 
Reid, 1999).  
4.2.4  Knowledge about hyperglycemia in pregnancy among pregnant women  
This study assessed knowledge of the pregnant women on HIP for appropriate interventions 
to be planned to prevent short and long-term effects of HIP to the mother and her newborn 
through self-care. It also included sources of information and general practices of screening 
and managing HIP to understand how pregnant women are screened for diabetes/GDM and 
managed as part of the antenatal care.  
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The majority of the pregnant women in this study had poor knowledge on the existence of 
HIP, which may increase the likelihood of associated effects as these women may continue 
with poor lifestyle choices regardless of their condition. This finding is in line with the 
behavior change model under the Health Belief Model which explains that, after having 
knowledge on different aspects of a health condition, behavior change occurs when people 
feel to be vulnerable and perceive the consequences of the condition as severe. Finally, 
individual’s behavior can change if they realize that taking action may either prevent or 
reduce the risk of the condition at an affordable cost (Irwin, 1974; Janz & Marshall, 1988). 
Low knowledge about HIP in the studied pregnant women may reflect that, the health system 
is not prioritizing HIP in the ANC as a risk factor for poor pregnancy outcomes as opposed to 
HIV, malaria, and tuberculosis which are given significant attention in current FANC 
guidelines. The standard treatments and essential medicines list guidelines include GDM 
screening using fasting plasma blood and 2 hours OGTT (MoHSW, 2013). This guideline 
also recommends the condition to be managed before and throughout pregnancy along with 
control of glucose levels by diet, oral hypoglycemic and/or insulin. The blood sugar should 
be maintained  within the range of 4-6 mmol/L throughout pregnancy and during labour the 
glucose needs to be checked after every 4 hours to detect any signs of hypoglycemia and 
managed it accordingly (MoHSW, 2013). Also, the same guidelines recommend monitoring 
of the blood sugar after delivery to adjust insulin requirements (MoHSW, 2013).  
Although there is sufficient information on GDM screening and management in some 
guidelines, these guidelines are seldom incorporated into the ANC services to meaningfully 
impact accessibility and affordability of this important intervention. It is imperative that the 
health care system integrate these guidelines into the ANC so that they can be consistently 
applied by the health care providers who typically adhere to such guidelines.  
The disintegrated information in the health system limits the health care providers in 
promoting and attending this pregnancy challenge in the ANC programs. This finding was 
consistent with a similar study in North Karnataka where most of the women had poor 
knowledge about GDM (Dhyani et al., 2018). However, a study conducted in Samoa reported 
that a high proportion of women (58%) were aware that GDM can occur initially during 
pregnancy and 23% indicated uncertainty and the remaining 19% were not aware of the 
disease at all (Price et al., 2017).  
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Knowledge about HIP in the current study was significantly associated with level of 
education where the majority of women with knowledge had attained secondary or 
college/university levels of education. On the other hand knowledge on HIP was not 
associated with occupation, income, age and gravidity after adjusting for education levels. 
The possible explanation is that educated women can easily search for information from 
different sources and may have obtained HIP knowledge at school either through training or 
sharing of experiences. A similar study from Ghana reported that pregnant women with 
higher levels of education were more aware of the risk factors associated with GDM and, 
possibly, its management and outcomes (Azu & Essel, 2017).  
In the current study, the level of income and occupation were not associated with knowledge 
after adjusting for education because most of the educated women were also employed and 
have high income compared with their counter parts. This finding mirrors a study from the 
urban areas of Chidambaram where no significant association between occupation and GDM 
knowledge was indicated (Lakshmi et al., 2018).  
It is also observed in this study that, age of the respondent was not associated with knowledge 
on the existence of HIP which may be due to fact that most of the young women were 
educated which might have influenced their level of knowledge. Another similar study 
supported that age of the woman was not significantly associated with knowledge about 
GDM (Elmekresh et al., 2017).  
Majority of pregnant women in this study have low knowledge on the effects of HIP to the 
mother or the newborn because very few understood that HIP can cause stillbirth, diabetes 
later in life to the mother and the newborn, as well as childhood and adult obesity. Low 
knowledge on effects of HIP may complicate the implementation of diagnosis, prevention, 
and management interventions as women may not see the importance of regular screening 
and prevention. This is because behavior change is greatly influenced by an understanding on 
the possible consequences of the condition. The current finding is supported by Bhavadharini 
et al. (2017) that most of the participants were unaware of the possible effects of GDM on the 
mother or the new born. Similarly, knowledge on the effects of GDM was poor as most of the 
women did not know its consequences after pregnancy and the increased risk for T2DM in 
future (Elamurugan & Arounassalame, 2016; Shriraam et al., 2013). 
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Most of the participants in this study were not informed on the risk factors for HIP, while this 
is a very important aspect of self-care as it can help in earlier self-identification for 
immediate action to prevent adverse pregnancy outcomes and long-life health effects. A 
similar study in India reported that, although a greater proportion of the women was aware of 
the conditions of diabetes mellitus (DM) and GDM, knowledge about the risk factors, causes 
of GDM, and future risk for T2DM was low (Shriraam et al., 2013). The same study stressed 
that proper precautions and self-care can be taken if women have good knowledge about the 
risk factors and the consequences that they may face due to untreated GDM (Shriraam et al., 
2013).  
The main source of information about HIP in the current study was reported to be different 
media, such as newsletters, radios, internet and television, what sap although of note very few 
women reported to have received the information from ANC. Most of the women declared 
that it was their first time to hear about HIP during the introduction of the current study. This 
finding affirms that most pregnant women do not have accessible important information 
regarding critical health issues.  
The appropriate source of information was expected to be the ANC but, it was the least used 
source, which is likely attributable to lack of HIP information within the ANC programs. This 
insight creates a need to incorporate HIP in ANC guidelines to enable healthcare providers 
include it in their day-to-day education programs for easier access by pregnant many women. 
The findings from the current study are in line with studies in India and Samoa which 
reported that, although it is encouraging to see the role played by mass media in creating 
awareness about GDM, the healthcare providers were mentioned as a source of information 
by very few women (Price et al., 2017; Shriraam et al., 2013). Another study reported that 
although the physicians and healthcare providers were mentioned as the source of 
information by only 19.4% of the studied women, the rest got it from the mass media or other 
sources however health care providers are still the most preferable source of information 
(Elmekresh et al., 2017).  
Hence, health care providers should be a reliable source of information to provide knowledge 
among antenatal women by including HIP in their routine health care education programs 
(Shriraam et al., 2013). Another study in Bangladesh reported that most of the GDM women 
obtained knowledge from their neighbors (47.6%) and family (42.9%) whereas both medical 
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professionals and neighbors (30%) provided knowledge among normal pregnant women 
(Monir et al., 2018).  
Majority of the women in the current study reported to been rarely screened for HIP in their 
previous pregnancies unless for those who shown to have symptoms where the common 
screening method used was glucose test in urine. A large proportion of pregnant women 
reported to have never being tested for GDM in their previous pregnancies implies that, HIP 
testing and management is not given priority in the ANC programs in Tanzania. Hence, many 
women may have undiagnosed GDM which can result into unfavorable pregnancy outcome 
and or later progress into T2DM.  
The women who were detected with glucose in urine in their previous pregnancy declared 
that they were referred to the doctor with no follow up from the ANC. This gap yields a need 
for monitoring and follow-up of these women to ensure that management is done 
appropriately. This finding is supported by a similar study done in 30 health facilities in 
Tanzania where urine tests for protein and glucose were commonly performed, but blood 
glucose testing was rarely done unless in the case of positive urine tests, suspect symptoms, 
or known diabetes diagnosis (Ramaiya et al., 2018). It was reported that some health facilities 
have never found any woman with glycosuria, which is likely due to low sensitivity of urine 
test strips in detecting GDM cases (Ramaiya et al., 2018).   
Also, in some facilities, incidence of HIP was very low likely due to missed opportunities 
caused by limited screening for diabetes and poor documentation. Similar to the current 
findings, Utz et al. (2017) found that the majority of the pregnant women are referred to 
either a general practitioner or a specialist after diagnosis of GDM. Another study conducted 
in rural India was inconsistent with these findings as pregnant women were screened for 
GDM using blood samples and monitored at least once weekly (Appajigol & Bellary, 2015).  
Although referrals are common due to lack of enough specialists for diabetes care in many 
developing settings, the additional costs may increase the rate of lost to follow-up and drop 
out (Beran & Yudkin, 2006; Nielsen et al., 2012). Hence, pregnant women can adhere to 
early diagnosis, follow up and general self-care interventions if they know their conditions 
and costs associated with unmanaged GDM.  
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4.2.5  Simple method for identification of women with/at risk of  gestational diabetes  
            mellitus 
The current study developed a risk score for Tanzania’s ANC settings to enhance self-care 
and evidence-based treatment. The observed high prevalence of HIP especially in a form of 
GDM may increase burden to the health system if no instant measures are taken. This created 
a need to explore for the associated risk factors to develop a simple method for selective 
screening to give priority to the high risk women due to limited recourses.  
 The developed risk score involved maternal and clinical characteristics, such as high MUAC 
≥ 28 cm, body fat ≥ 38%, family history of T2DM and history of delivery macrosomic babies 
(≥ 4 kg) at birth. Macrosomic delivery is a pregnancy outcome which implies that, more 
glucose was transferred from the mother to the fetus, resulting into more weight gaining for 
the fetus. The healthcare interventions on screening and managing GDM can target women 
with these risk factors to reduce their risks of developing GDM.  In this case family history of 
T2DM, was identified as being a more important predictor for GDM followed by tendency of 
delivery macrosomic babies, body fat ≥ 38% and lastly MUAC ≥ 28 cm with the lowest 
score.  
This risk score was found to perform well with an AUC of 97%, implying that the developed 
risk score can strongly discriminate the randomly selected women who are experiencing 
GDM from those not experiencing the condition. Furthermore, this risk score model was 
compared with fasting, OGTT and urine glucose test models and found to perform better than 
the other three models followed by the fasting and OGTT models, while urine glucose test 
model was invaluable. This implies that, if urine sample is used as a solely method to screen 
for GDM, most of the pregnant women with GDM would be left undiagnosed.  
This is observed in the current study whereby only 0.9% of the pregnant women with GDM 
were identified using urine samples. This is supported by a study done in Tanzanian health 
facilities which revealed that glucose testing using urine samples is a common practice in 
ANC however, due to its insensitivity, a large proportion of women with or at risk of GDM 
remain undiagnosed (Ramaiya et al., 2018). Another study supports that, as in most low-and 
middle-income healthcare settings, reagent-strip glycosuria testing is a routine ANC practice 
in Ghana and diagnostic decision is made based on its outcome (Agbozo et al., 2018).   
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Furthermore, the utility of the risk score model was assessed using a net benefit (NB) curve 
and the NB of using the risk scoring model was compared with the NB of testing all patients 
or testing no patient. In this case, it was found that the risk score model has higher NB at any 
given threshold compared to universal and/or not testing any woman. This implies that, the 
model has high clinical value in the studied population as most as the women (more than 
80%) with high risk can benefit from the screening program.  Another study reported that the 
presence of risk factors followed by 1-hour OGTT and FPG models were more sensitive 
compared with glycosuria, random blood glucose and glycated hemoglobin, which were 
highly insensitive and diagnostically poor, and hence missed majority of the GDM cases 
(Agbozo et al., 2018).   
The developed tool has an ability to identify about 98% of the pregnant women with positive 
result and 46% of truly negative women at the selected threshold of 0.2. This means that it 
can correctly identify most of the women with or at risk of GDM in these ANC settings to 
allow additional testing to few women for further actions to be taken to prevent short- and 
long-term health effects to the mother and the newborn. The application of this tool will also 
potentially increase efficient use of the scarce resources to enhance treatment based practices 
to give priority to the high risk women to reduce costs and inconveniences.  Several similar 
studies have been conducted to develop selective screening methods and found that the 
strategies perform well in reducing unnecessary testing and increase early identification of 
women with or at risk of GDM (Sweeting et al., 2017; Harrison et al., 2015; Fawole et al., 
2014; Teede et al., 2011; Caliskan et al., 2004; Zheng et al., 2019; Artzi et al., 2020). These 
results encourage the use of selective screening for early identification of women at risk of 
GDM and/or in areas with limited resources.  
Most of the already published selective strategies have been developed using variety of risk 
factors for example a similar study was conducted in Tanzania and developed a selective 
screening tool which involved MUAC ≥ 28 cm, stillbirth and family history of diabetes with 
an ability to identify 69% of the GDM women (Nombo et al., 2018). The slight disparities 
observed in this model with the current study’s model, may be due differences in diagnosis 
criteria where the current study used the WHO (2013) criteria with low threshold values and 
the previous study used the WHO (1999) criteria with high threshold values (Nombo et al., 
2018). It might also be due to inclusion of more risk factors including body fat percentage 
that can replace BMI although not very well explored. Another study done in Nigeria 
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reported that; history of diabetes mellitus (DM), tendency of delivery to macrosomic baby, 
and history of previous unexplained stillbirth were predictors of GDM hence, they were 
included in the risk factor checklist for screening GDM (Fawole et al., 2014).  
On the other hand, Caliskan et al. (2004) developed a risk score which included maternal age, 
BMI and first-degree relatives with diabetes mellitus, a prior macrosomic fetus (> 4000 g) 
and adverse outcome in the previous pregnancies. Their score was found to have an ability 
for decreasing the number of women to be screened by 63%, still diagnosing 85% of cases 
with GDM showing a good performance of the model. This supports the current results 
partially, but varies as it included BMI which was difficult to determine in the current study 
setting. Other studies done in Nigeria and China were also contrary to these findings because 
they reported that the pre-gestational BMI > 25 kg/m2 was a determinant of GDM (Nielsen et 
al., 2016; Zheng et al., 2019). This varied from the current findings as most of the women 
could not recall their pre-pregnancy weight and were late to start ANC with an average of 18 
weeks of gestation which made it in-determinant during pregnancy. Instead, the current study 
used body fat percentage in addition to MUAC as a proxy for BMI because it can easily be 
measured during pregnant as well as post-delivery.  
Also, body fat percentage is a good indicator of fat deposition compared to BMI which may 
be affected by weight of the fetus and the fluids which accumulate during pregnancy. A study 
done in India reported that the estimation of weight for determining BMI may be susceptible 
to certain bias as it is partly based on self-reported weight or weight measured at first 
antenatal care visit potentially leading  to over-or under-estimation of BMI (Nielsen et al., 
2016). 
Maternal age was not significantly associated with development of GDM in the current study 
which may be attributed by changes in life style that has made more young women to be 
overweight/obese with high risk of developing NCDs including GDM. Another similar study 
reported that, by definition the selective strategy detects more cases of GDM among older 
women with higher BMI and misses more cases among younger women with lower body-
mass indexes. Therefore, it is very unlikely that this shift in detection patterns is harmful 
(Naylor et al., 1997). Another model which was developed in China for early screening of 
GDM was contrary to the current developed model because age was found to be a good 
predictor of GDM (Zheng et al., 2019). It is also reported that due to higher fertility rates in 
younger women, nearly half (48.9%) of all cases of HIP (that is GDM and DIP) occurred 
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among women under the age of 30 years (IDF, 2017).  This is also supported by similar study 
which reported that, the age of onset of diabetes mellitus and pre-diabetes is declining (Hod 
et al., 2015).  
Insulin resistance was positively associated with GDM in this study but it could not be 
involved in the risk score development due to its associated diagnostic costs, as the aim of the 
current study was to develop a simple and cost-effective method. However, as IR was 
associated with hypertension and presence of edema, which are indicative of preeclampsia, 
these factors were included in the final risk factors checklist to involve women with IR but 
not yet developed GDM.  A similar study reported that women with GDM are more likely to 
experience IR than their non-GDM counterparts (Elkind-Hirsch et al., 2010).  
Furthermore, increased serum insulin level at screening in early pregnancy can predict GDM 
as it is reported that, the higher the serum insulin level, the earlier the manifestation of GDM 
(Bitó et al., 2005). In this case, the inclusion of risk factors for IR is important for early 
identification of women at risk of GDM to prevent the development of GDM, and T2DM as 
insulin is an indication of future diabetes. This finding makes the developed tool to be very 
useful in early identification of women at increased risk for GDM even before pregnancy for 
immediate preventive actions to be taken to prevent short and long-term health effects to the 
mother and her new born.  
Based on the current developed tool with factors that can be assessed even before or in the 
early stage of pregnancy, most of the women at risk of GDM could be identified before or 
during pregnancy to allow timely intervention to improve maternal and neonatal outcomes. 
Moreover, monitoring and testing of women for GDM throughout pregnancy can be 
performed according to the need of the individual patient (van Leeuwen et al., 2010) hence, a 
more personalized approach to the health care interventions.  It is also reported that a better 
understanding of the risk factors for GDM may not only add to the knowledge of the 
pathways leading to GDM, but also inform and enable health care providers to focus on 
women at increased risk for whom earlier and repeated screening may be of greatest 
importance (Nielsen et al., 2016). Another similar study developed selective models and 
found that they may allow early-stage intervention in high-risk women, as well as a cost-
effective screening approach that could avoid the need for glucose tolerance tests by 
identifying low-risk women (Artzi et al., 2020). 
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Contrary to the current findings several studies have reported that risk factors have poor 
predictive value and fail to identify a large proportion of women with GDM which limits 
their use (Adam & Rheeder 2017; Matta-Coelho et al., 2019; Agbozo et al., 2018). Another 
review was done to validate 12 published GDM risk scores and reported that the most 
common predictors were age, adiposity, family history of diabetes, history of GDM, 
ethnicity, and history of macrosomia. The reviewed scores performed only moderately 
therefore, requested for more research to be done before putting the scores into practice 
(Lamain-de Ruiter et al., 2016; Huvinen et al., 2018).  In line with this, some meta-analysis 
suggest that irrespective of the method used, risk factors do not identify women with GDM 
well (Farrar et al., 2017), but it is still important to consider these selective screening as they 
can help in  early identification of women at risk for timely management especially in 
resource limited areas. Another study done in Nigeria reported that a checklist of risk factors 
for GDM should be included their antenatal protocols to ensure proper identification of 
women with GDM is done thoroughly (Fawole et al., 2014).  
Some researchers in India attempted to develop a risk factor based scoring variables for 
screening GDM, but none of the risk factors or their accumulation were strong enough to 
clearly discriminate between those with and without HIP in all their settings, emphasizing the 
need for universal screening for GDM/DIP (Nielsen et al., 2016). Universal screening is 
highly recommended given availability of financial, material, space and human resources 
however it needs implementing multiple testing during pregnancy for all women which is not 
only costly, but operationally challenging (Nielsen et al., 2016). This makes selective 
screening using maternal and clinical characteristics to be important especially in low income 
countries with limited resources.   
For operationalization of the developed risk score which was simplifies into a risk factors 
checklist, the health system needs to integrate it into the ANC services from the point of entry 
with  history taking and throughout  during counselling and regular education programs. This 
tool can be effective if it is used at the first ANC and in subsequent visits as some of the risk 
factors can arise at the middle or late stages of pregnancy. This will increase knowledge 
about GDM as a risk for poor pregnancy outcomes. When a woman is identified having one 
of the risk factors in the checklist, can be referred to the doctor for more actions to be taken 
as what is done in other conditions indicated in the FANC guideline (Kearns et al., 2014). 
This can help to give priority to high risk women when resources are limited while planning 
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for universal screening, which needs more resources. The developed tool can also be used by 
women for self-identification even before pregnancy to enhance proper preconception 
preparations.  
4.3  Limitation of the study  
Although results from this study are encouraging, the study was conducted in a population 
which is ethnically homogenous Africans, which limits generalizability of the findings. 
Moreover, the study involved a small sample size that resulted in wider CIs in some of the 
associations among variables which may reduce the precision of the study due to distribution 
effect. However, the study is still useful as it is a bases for an additional longitudinal study 
with large sample and improved follow-up methods.  
 
4.4  Methodological challenges in the current study 
The study faced biases on data collection where participants had to recall some information 
such as pre-pregnancy weight which may lead into over- or- underestimation. Hence to avoid 
this biasness, body fat percentage and MUAC were used to assess nutrition status of the 
pregnant women to replace BMI. Among 24 health facilities with both ANC and delivery 
services, only 2 centers were selected, which may not be representative of the health 
facilities, leading to bias in extrapolation as we  cannot  feel  confident  that  these  results  
will  serve  as  a  parameter of the urban population. This is because, internal and external 
validity are undermined.   
 
Hence, random sampling was used to reduce this biasness effect. Furthermore potential 
confounders between dependent and independent variables during data analysis were 
identified including maternal age, income and parity. These confounders were controlled by 
running multivariate analysis to reduce their effects on associations among variables 







CONCLUSION AND RECOMMENDATIONS 
5.1  Conclusion  
The prevalence of HIP, especially in the form of GDM, was high in urban areas of Arusha 
City and significantly associated with family history of T2DM, tendency of delivering 
macrosomic babies (≥ 4 kg), MUAC ≥ 28 cm and high body fat ≥ 38%. Likewise, the 
prevalence of IR was higher among pregnant women with family histories of T2DM, high 
body fat percentage, presence of edema, and hypertension. Screening and management for 
HIP is not a common practice in the antenatal services offered in Tanzania, which creates a 
scenario in which the condition is not given priority in the health care system as a risk for 
poor pregnancy outcomes.  
Universal screening for IR or HIP (GDM and DIP) and early intervention may help to reduce 
the associated complications, but very expensive, which created a need to develop a risk 
score. The developed risk score was found to perform well as it was able to predict 98% of 
high-risk women compared to the universal screening of all pregnant women. Hence, it was 
simplified into a risk factors checklist for ease of interpretation and application. Conversely, 
knowledge about HIP was very low among the participated pregnant women and influenced 
by maternal education levels. The main source of information about HIP was reported to be 
social and mass media while care providers were expected to be the reliable source of this 
important health condition. 
5.2  Recommendations 
Hyperglycemia in pregnancy is a substantial health problem however, it has received minimal 
attention from the health system. This calls for the policy makers to strengthen the ANC 
programs to include routine HIP screening, diagnosis, management and follow-up to prevent 
short and long-term effects to the mother and the newborn. To be effective the national health 
policy needs to be amended to recommend routine screening for GDM using universal 
strategies with sufficient resources or selective screening when resources are limited to give 
priority to the high-risk women.  
74 
Hence, to adopt either universal or selective screening, different health stakeholders should 
join efforts to validate these findings using a large longitudinal national study with large 
sample size representing all regions of the country. Furthermore, a trial of the validated tool 
should be done in one of the zones in the country. The health system needs to integrate 
different health stakeholders in prevention of HIP (GDM and DIP) through regular ANC 
education programs using different media to enhance self-care to address the various risk 
factors. This can help in proper preconception preparations, care during pregnancy, and post-
delivery period. The health system is fragmented which may reduce efforts to solve related 
conditions. Hence, there is a need for the health system to amend different NCDs strategies, 
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APPENDICES 
Appendix 1: Research tool (Questionnaire) 
THE NELSON MANDELA AFRICAN INSTITUTION OF SCIENCE AND 
TECHNOLOGY  
(NM – AIST) 
 
Questionnaire on prevalence of hyperglycemia in pregnancy, risk factors and simplified 
method for identification of pregnant women at risk in Arusha, Tanzania 
S/N Section A: General information  Fill blanks/Tick where appropriate  
1 Interviewers name    
2 Center  Name (ANC  name )    
3 Name of respondent (Three names)    
4 Ward     
5 Street     
6 Date of  interview     
7 Consent obtained Yes  1  
No   2  
8 Contact  phone  number of  respondent     
 Alternative numbers     
9 Who is the owner of the phone number? Yours       1  




10 At what gestational age did you start visiting 
clinic?  
Write in weeks  ----  
11 What is the mother’s gestational age 
currently?  
Write in weeks  -----  
12 What is your expected date of delivery? Write the data and 
month 
-----  
Section B: Demographic information 
13 What is your age or date of birth? Date ----- Years ----- 
14 What is the highest level of education that you 
have attained? 
Never went to school 1  
Primary school 2  
Secondary school 3  
college/university 4  
96 
15 What is your marital status? Never married  1  
Married 2  
Separated 3  
Divorced 4  
Widowed  5  
Cohabiting 6  
Refused to mention 99  





Self employed  2  
Student  3  
Home maker  4  
Retired officer  5  
Unemployed  7  
Disabled  8  
Others (mention) 9 ---- 
17 What is your average income per month?  <250,000 1  
250,000-450,000 2  
500,000- 750,000 3  
800,000-1,000,000 4  
>1,000,000 5  
Others (mention) 6  
Refused to mention 99  
Section C: Risk factors for HDP (present and past records) 
18 Which birth order is this pregnancy?  First 1  
Second  2  
Third  3  
Fourth  4  
>Fourth  5  
19 What is the age of your youngest child? Write in Months  ----  
20 Have you ever delivered ≥4kg child 
previously? 
Yes 1  
No 2  
I don’t know 88  
21 Have you ever delivered a pre-term baby? 
(Delivery before  37 weeks of gestation)  
 
Yes 1  
No 2  
22 Have you ever got a prenatal death? Yes 1  
No 2  
23 If yes, how many times? Once 1  
Twice  2  
Thrice  3  
>Thrice  4  
97 
24 Have you ever have a perinatal death? Yes 1  
No 2  
25 If yes, how many times? Once 1  
Twice  2  
Thrice  3  
>Thrice  4  
26 Do you have any history of diabetes in your 
family? 
(your grandfathers/mothers or  your 
parents/sister/brother) 
Yes  1  
No 2  
I don’t know  88  
27 Did your mother have any history of HDP? Yes  1  
No 2  
I don’t know  88  
28 Did you measure your sugar levels in your 
previous pregnant? 
Yes 1  
No 2  
I don’t know  88  
29 If yes, how was it tested  Urine 1  
Blood 2  
30 If yes what was the status? Normal 1  
High (diabetes) 2  
I don’t know  88  
31 If it was high, were you treated and followed 
up? 
Yes 1  
No 2  
32 If yes, how was it treated? Given medication 1  
Education 2  
Referred to diabetic 
clinic for counseling  
3  
33 What was the mode of delivery in your 
previous pregnant? 
Normal delivery 1  
Cesarean session  2  
Others (specify) -  
34 If it was cesarean session, what was the 
reason?  
Big baby 1  
Poor positioned baby 2  
Others (specify) 3 ----- 
I don’t know  88  
35 Have you ever been hypertensive in your 
previous pregnancies  
Yes 1  
No 2  
I don’t know    
36 What was your weight during the first visit to 
clinic  
Write in Kg  ------  
  I don’t know  88  
37 What is your ethnicity? Black 1  
White  2  
98 
38 Are you smoking currently? Yes 1  







39 If yes how many cigarettes per day? At least one  piece  -  
Two pieces   
Three pieces   
More than three 
pieces 
  
40 Are you consuming alcohol? Yes 1  







41 If yes how many bottles per day? At least one bottle  1  
Two bottles 2  
Three bottles 3  
More than three 
bottles 
4  
Section D: Knowledge about HIP  among women 
42 Do you know the existence of HIP? Yes 1  
No 2  




Others (specify) 3 -- 
44 Did you test glucose in this pregnancy? Yes 1  
No 2  
I don’t know  88  
45 If yes, how was it measured? In the urine 1  
Fasting blood  2  
OGTT 3  
Others (specify) 4 -- 
I don’t know 88  
46 How were the results? Normal 1  
Hyperglycemic 2  
Hypoglycemic 3  
I don’t know 88  
47 Are you know the meaning of HIP?  Yes 1  
99 
No 2  
48 If yes can you define it? Diabetes first 
detected in pregnancy 
1  
Hereditary Diabetes  2  
Others (Specify) 3  
49  Are you are of the symptoms of HIP? Yes 1  
No 2  
50 If yes mention them Frequent thirst 1  
Frequent urination  2  
Vision impairment  3  
Others mention  4 - 
51 Do you know the effects of HIP? T2DM to  the baby 1  
Death of the baby 2  
Macrosomic baby 3  
Overweight/obesity 4  
Others(specify) 5 - 
52 Do you know the causes of HIP? Yes 1  
No 2  
53 If yes mention the causes of HIP? Overweight/obesity 1  
Previous GDM 2  
Family history of 
T2DM 
3  
Genetics  4  
Poor Eating behavior  5  
Others(specify) 6 - 
54 Do you have anything to say? Questions, 
suggestion, opinions  
   
 
 
Section E: Measurements during pregnancy 
Respondent ID  
Respondent name   
Gestational week   
Weight before pregnancy  
Anthropometric      Variables Measured 
SN Variable 1 2 3  
1 Weight      
2 MUAC     
3 Body fat     
4 Blood pressure     
5 Presence of  edema  1. Yes    
2. No    
100 
Blood glucose tests  
 1 Fasting blood glucose     
2 OGTT     
3 Serum insulin level     
Urine test 4 Urine glucose      
5 Urine Protein test   
                                                     Thank you for your corporation  
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Appendix 2: Consent form for the cross-sectional study  
Introduction 
Hyperglycemia in pregnancy (HIP) is impaired glucose tolerance with onset or first 
recognition during pregnancy. In most cases, blood glucose return to normal after delivery 
but there are higher chances for future diabetes to the mother and the child. Studies show that 
early identification and management of HIP prevents adverse pregnant outcomes. This study 
will help to establish the prevalence of HIP and its associated risk factors and develop a risk 
factor score system that can be used as easy, noninvasive and less cost method of screening 
for HIP to avoid unnecessary universal screening but save the lives of mothers and their new 
bones. To complete this work we will take your blood and urine samples to measure glucose, 
serum insulin, urine protein and anthropometric measurements as well as requesting to 
answer some questions in a questionnaire.    
Procedure: If you consent to participate in this study, you will be requested to come 
tomorrow before eating anything and your blood will be drown from the venous for checking 
fasting blood glucose and serum insulin status. To confirm your glycaemia status, you will be 
given glucose solution (75 grams dissolved in 300ml of water) to drink and blood will be 
taken after one and two hours and tested for glucose concentration. The results of your test 
will be disclosed to you and its implication will be explained. Your blood will be stored and 
used for the purpose stated in this study only.   
Benefits: By participating in this study, your blood sugar, blood pressure, insulin resistance 
will be measured free of charge and provided with advice and counseling. You may be 
referred for more tests and managements if necessary.  
Risks and precautions: We will request you to remain fasting for at least eight (8) hours at 
night before you come for the test, not smoke or take alcohols. We will request you to wait 
for two hours after drinking glucose solution without eating anything. Well trained and 
experienced personnel will be involved during blood collection to ensure minimal discomfort.  
No risks are involved in drinking glucose solution; however, you might have some 
inconveniences like nausea, slight headache or tiredness. 
Confidentiality: Any records relating to your participation will be strictly confidential.  Your 
names will not be used in any reports from the study. The participation to this study is 
voluntary and may withdraw from the study at any time. You are free to ask any questions or 
any clarification after you have read and understood the consent form explained to you. 
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Participant statement 
I---------------------have understood the above information explained to me by the investigator 
and I agree to take part in this study and I can withdraw with or without giving reasons.  
Participant’s Name:……………………………Signature………………… Date………….. 
Investigator’s  Name :…………………………Signature ………………....Date…………..  
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Appendix 3: Ethical clearance certificate  
Appendix 3: Ethical clearance  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
